USAID GLOBAL HEALTH SUPPLY CHAIN PROGRAM

PROCUREMENT AND SUPPLY MANAGEMENT

Situation analysis:

Contraceptive Manufacturing in Pakistan

September 2020

This publication was produced for review by the United States Agency for International Development. It was prepared by Chemonics International Inc.



This publication was produced for review by the United States Agency for International Development and Ministry of National Health Services, Regulation and Coordination (MoNHSR&C) – Population Planning Wing (PPW). It was prepared by Chemonics International Inc. under Global Health Supply Chain Program - Procurement and Supply Management (GHSC-PSM) Contract No. AID-OAA-I-15-00004 and Task Order 03 Contract No. AID-OAA-TO-15-00010.

Recommended citation: USAID Global Health Supply Chain – Procurement and Supply Management Single Award IDIQ. 2016. USAID GHSC-PSM report on situation analysis on feasibility to explore the potential of local production of contraceptives in Pakistan, Chemonics International Inc.

Chemonics Contact:

Muhammad Tariq Country Director – GHSC-PSM Pakistan National Science and Technology Park (NSTP) NUST, H12, Islamabad, 44000, Pakistan +92 333 5555 291 <u>mtarig@chemonics.com</u>

Situation analysis – contraceptive manufacturing in Pakistan

Contents


Context1
Background 3
Methodology7
Public Sector Contraceptive Projection with Costing (2020-21 to 2029-30) 8
Private Sector Contraceptive Projection with Costing (2020-21 to 2029-30)9
Punjab - Public Sector Contraceptive Projection with Costing (2020-21 to 2029-30)10
Punjab - Private Sector Contraceptive Projection with Costing (2020-21 to 2029-30)11
Sindh - Public Sector Contraceptive Projection with Costing (2020-21 to 2029-30)12
Sindh - Private Sector Contraceptive Projection with Costing (2020-21 to 2029-30)13
Khyber Pakhtunkhwa - Public Sector Contraceptive Projection with Costing (2020-21 to 2029-30)14
Khyber Pakhtunkhwa - Private Sector Contraceptive Projection with Costing (2020-21 to 2029-30) 15
Balochistan - Public Sector Contraceptive Projection with Costing (2020-21 to 2029-30)16
Balochistan - Private Sector Contraceptive Projection with Costing (2020-21 to 2029-30)17
Investment Growth Potential19
Way Forward24
Annexure-I: PPW request for commissioning study25
Annexure- II: USAID Pakistan concurrence to the PPW request27
Annexure- III: Public sector contraceptive data (2007 – 2010)28

Acronyms

COC	Combined Oral Contraceptive
DMPA	Depot Medroxyprogesterone Acetate
DOH	Department of Health
ECP	Emergency Contraceptive Pill
FP	Family Planning
GoP	Government of Pakistan
GHSC	Global Health Supply Chain
GHSC-PSM	Global Health Supply Chain – Procurement and Supply Management
IDIQ	Indefinite Delivery Indefinite Quantity Contract
IMR	Infant Mortality Rate
IUD	Intrauterine Device
LMIS	Logistics Management Information Systems
MoNHSR&C	Ministry of National Health Services Regulations & Coordination
MMR	Maternal Mortality Rate
NGO	None Governmental Organization
POP	Progesterone Only Pill
PPW	Population Program Wing
PSM	Procurement and Supply Management
ROI	Return on Investment
то	Task Order
U5MR	Under 5 Mortality Rate
UNFPA	United Nations Population Fund
USAID	United States Agency for International Development

CONTEXT

In 1950, Pakistan's population reached 37 million people, making it the world's 13th most populous country. By 1998, Pakistan was ranked as world's sixth most populous country. The Census 2017 records 207.7 million habitants within Pakistan, placing it now as the fifth most populous country in the world. As per UN estimates, Pakistan's population is geared to rise to 380 million by 2050 (Figure-1) and is likely to surpass Indonesia, Brazil, Russia, and the United States. This projected growth would further strain water, forests, and arable land resources as well as reverse the economic gains made in recent years.






Figure 1: Pakistan Population Growth (Source: UN Department of Economic and Social Affairs Population Dynamics, World Population Prospects 2019 https://population.un.org/wpp/Graphs/Probabilistic/POP/TOT/586)

increased contraceptive use. Contraceptive use reduces overall maternal mortality and improves women's health by preventing unwanted and high-risk pregnancies and reducing the need for unsafe abortions. This has a direct correlation with child and family well-being by reducing the economic and emotional burden of parenthood and affording increased opportunities for participation in educational, economic, and social activities.

As per the Economic Survey of Pakistan 2019-20 and FP2020 Commitment, Pakistan fares poorly on
some of the key indicators are listed in the table below:

SDG (target by 2030)	Current standing ¹
MMR: < <u>70 per 100,000</u> live births	140/100,000(2017)
IMR: < <u>12 per 1,000 live births</u>	57.2/1000 (2018)
U5MR: < <u>25per 1,000</u> live births	69.3/1000 (2018)
FP2020 (target by 2020)	Current standing ²
Contraceptives Prevalence Rate (CPR) 50%	CPR 34.2%
Contraceptives Prevalence Rate (CPR) 55% for Punjab	CPR 38.3%
Contraceptives Prevalence Rate (CPR) 45% for Sindh	CPR 30.9 %
Contraceptives Prevalence Rate (CPR) 42% for Khyber Pakhtunkhwa	CPR 30.9 %
Contraceptives Prevalence Rate (CPR) 32% for Balochistan	CPR 19.8%

Pakistan is committed to achieve SDGs by reducing Maternal Mortality Rate (MMR), Infant Mortality Rate (IMR), Under 5 Mortality Rate (U5MR) and ensuring universal access of reproductive health care services which include integration of reproductive health into national strategies and programs. The federal and provincial governments in Pakistan responded with political commitment by mobilizing sufficient allocation of \$130m until FY2019-20. Contraceptive services are now included in the essential package of health services, developed by provinces to improve service delivery and include facility-based and outreach services.

Although Pakistan was one of the first Asian countries to begin a family planning program with some help

¹ Economic Survey of Pakistan 2019-20

² Pakistan Demographic and Health Survey 2017-18

Situation analysis – contraceptive manufacturing in Pakistan

from international donors, fertility declined slower than in neighboring countries. Through the commodity assistance provided by the United Nation Population Fund (UNFPA) in the 1990s, Pakistan strived to reduce the population growth and brought it down from 4.5% per year to 2.9%. This support lasted until FY1999.

Subsequently, from FY2000 to FY2004, the Government of Pakistan (GoP) started sourcing contraceptives from UNFPA using the World Bank's withdrawal application procedure. With the enactment of public procurement rules in FY2004, the former health and population ministries embarked upon procurement of contraceptives through open competitive bidding for the locally manufactured contraceptive products; however, they continued using UNFPA platform for commodities not manufactured in Pakistan. The GoP's annual investment on family planning commodities during FY2000 - FY2009 remained steady at \$5-6 million, which was far below the actual requirements.

From FY2010 - 2015, USAID worked with the GoP and donated contraceptive commodities worth \$108m through supply chain programs to relevant public and private sector stakeholders across the country. Table I indicates USAID's yearly cost of commodity support to the GoP.

During FY2012 - FY2015, USAID also provided financial support worth \$1.5m to federal and provincial governments for transportation of contraceptive commodities from the Central Warehouse, Karachi to district stores across the country.

Co	st in million
Fiscal Years	Support
2010-11	\$10
2011-12	\$20
2012-13	\$20
2013-14	\$20
2014-15	\$38
Total	\$108

Table 1: USAID's commodity support from 2010 till 2015

Owing to the total commodity support provided by USAID during the

period indicated above (2010 to 2015) and recognizing the needs of forecasting and supply planning for concrete domestic financing, USAID initiated country-wide technical assistance on procurement and supply management. The GoP took this support positively and initiated domestic financing starting with Sindh and Punjab provinces in 2015. The commercial sector's share shrunk as they were not able to liquidate their business during 2010-2014. However, by 2015 local manufacturers and transporters were benefitting from the domestic financing of contraceptives by the provincial governments.

Another important stakeholder in the distribution of contraceptives has been the private sector i.e. NGOs who were historically supported by the Government of Pakistan. Their FP commodities future requirement until 2030 out of the total contraceptive ecology in Pakistan is presented in the private sector projection table appearing later in this document.

Year	GoP Financing
2014-15	\$16.09m
2015-16	\$18.25m
2016-17	\$21.81m
2017-18	\$25.89m
2018-19	\$25.19m
2019-20	\$22.37m
Total	\$129.60m

Realizing the significance of investments in family planning (FP) commodities, all provincial governments have clearly demonstrated their commitments by making allocation for FP commodities procurement as an integral part of their financial planning. Table 2 contains funds planned by the respective provinces of the Government of Pakistan who have so far committed ~\$130m for procurement of FP commodities until 2020.

Table 2: GoP committed financing till FY 2020

With a bourgeoning population as well as the contextual situation narrated above, the Population Program Wing (PPW) of the Ministry of National Health Services Regulations and Coordination (MoNHSR&C) had sought technical assistance from the United States Agency for International Development (USAID) mission in Islamabad to support them in conducting a situation analysis on feasibility to explore the potential of local production of contraceptives in Pakistan. USAID/Pakistan tasked the Global Health Supply Chain Program – Procurement and Supply Management (GHSC-PSM) project with the provision of this technical assistance along the lines mutually agreed upon in a tripartite meeting between PPW, USAID/Pakistan, and the GHSC-PSM project held on March 16, 2017 in Islamabad.

As per 2017 census results, with 110 million inhabitants, Punjab has become the most populous province of Pakistan. Additionally, more than half of its population resides in urban centers. The current contraceptives prevalence rate stands at 38.3%³ as against of FP2020 commitment of 55% by the Government of Punjab⁴.

With 48 million inhabitants, Sindh has become the second most populous province after Punjab. Additionally, more than half of its population resides in urban centers. The current contraceptives prevalence rate stands at 30.9% as against of FP2020 commitment of 45% by Government of Sindh⁵. Sindh has traditionally been a trendsetter in pioneering new FP methods using creative approaches to increase uptake of long acting contraceptive methods. Population Welfare Department of Government of Sindh was the first one to make sure this innovation of long acting method succeeds. Sindh PWD devised and sponsored strategies by creating champions for innovation, provided training to the healthcare providers and managed conflicting priorities and molds of the groups through communication techniques and social marketing.

With approximately 30.5 million inhabitants, Khyber Pakhtunkhwa has become the third most populous province after Punjab and Sindh with a population growth rate of 2.89. The current contraceptives prevalence rate stands at 30.9% as against of FP2020 commitment of 42%⁶ by Government of Khyber Pakhtunkhwa⁷.

As per census results of 2017 census, with 12.3 million inhabitants, Balochistan is the least populous province of Pakistan with a population growth rate of 3.37. The current contraceptives prevalence rate stands at 19.8% as against of FP2020 commitment of 32% by Government of Balochistan⁹.

BACKGROUND

The PPW of MoNHSR&C had initiated a request to the USAID Pakistan Mission in Islamabad to provide technical assistance to commission a feasibility study on local manufacturing of contraceptives in Pakistan. A formal request and action plan was sent by PPW to USAID/Pakistan through letter No. 12-2/2017-P&S dated April 26, 2017 (Annexure A) citing a meeting held with the USAID Pakistan Mission on March 16, 2017 which was followed by meeting with GHSC-PSM project on March 22, 2017. USAID/Pakistan agreed and informed PPW through letter dated May 9, 2017 (Annexure B) about assigning the provision of the assistance through the GHSC-PSM project.

To follow up on the TA, the GHSC-PSM project team started working on extracting contraceptive logistics data from government owned web-based logistics management information system (LMIS) <u>www.lmis.gov.pk</u> from 2010 through 2017. As data for the study was required from 2007, the project team met with the PPW on June 15, 2017 to devise a plan of action for conducting the feasibility study

Situation analysis – contraceptive manufacturing in Pakistan

³ Pakistan Demographic and Health Survey 2017-18

⁴ http://www.pwd.punjab.gov.pk/fp2020

⁵ http://pwdsindh.gov.pk/Publications/e-books/CIP%20Sindh-03%2015%2016-final.pdf

⁶ http://kp.gov.pk/uploads/2017/03/CIP_on_Family_Planning_for_Khyber_Pakhtunkhwa_2017-21_Final_Draft.pdf

⁷ Pakistan Demographic and Health Survey 2017-18

⁸ Pakistan Demographic and Health Survey 2017-18

⁹ <u>http://www.pbs.gov.pk/sites/default/files//social_statistics/Contraceptive%20Performance%20Report%202017-18.pdf</u>

which included a desk review of existing FP practices including method mix, quantities ordered, and consumption over the past 10 years. PPW was to develop a data acquisition template to obtain data from all provinces and was to share contraceptive procurement and consumption data from 2007 - 2010. Procurement and consumption data from 2010 onwards was extracted by GHSC-PSM project from USAID-funded annual contraceptive procurement tables and contraceptive LMIS, respectively.

In order to present an informed economic case to potential manufacturers, PPW, USAID/Pakistan, and GHSC-PSM devised a strategy to garner accurate procurement and consumption data for the past ten years, focusing on the projection of demand of the method mix through 2030 in light of Pakistan's international level commitments to targets identified in the National Health Vision-2025 as well as Sustainable Development Goals-3.

The GHSC-PSM project in collaboration with the PPW MoNHSR&C came up with the development of the situation analysis report in 2017, containing demand projections of the method mix from 2017-30. MoNHSR&C in collaboration with GHSC-PSM project convened a consultative meeting in Karachi under the Chairmanship of Director General PPW/MoNHSR&C on October 11, 2018 of key public and private sector stakeholders to discuss the landscape of opportunities in local production of contraceptives as well as vision of the Government of Pakistan towards indigenous contraceptives' production in addition to regulators' perspective towards creating conducive and enabling environment for investors in this area. The provincial Population Welfare Departments as well as Health Departments, who are the main stakeholders for dispensing contraceptives at the service delivery points were also invited to be part of the consultation.

The event was attended by a variety of national and international pharmaceutical companies' representatives, high level government functionaries from both Federal and Provincial governments, regulators like Securities and Exchange Commission of Pakistan (SECP) as well as Drug Regulatory Authority of Pakistan (DRAP).



Figure 2: Meeting with pharma industry – Oct 11, 2018

In pursuance to action point regarding contraceptive local production of the 3rd Federal Task Force meeting held on August 6, 2020, under the chairmanship of Excellency, the President of Pakistan, the GHSC-PSM project had a meeting with the Honorable Special Advisor to the Prime Minister (SAPM) on Health, Dr. Faisal Sultan; Secretary Health, MoNHSR&C and their teams on August 31, 2020, at the Ministry. Given the study was conducted in 2017, the Secretary Health suggested to update the FP business forecast having ten years of projections. As a follow-up of the meeting, the report at hand is the updated version containing demand projections of the method mix from 2020 to 2030. The statistics here present plausible justification to expect that the sheer population size and the demand for contraceptives in view of the foregoing commitments are sufficient to lure investors to venture into local production of contraceptives.

In addition to delineating a holistic landscape of contraceptives consumption for the entire country, the provincially desegregated quantities and financial outlays have also been made available for the respective provincial governments in order that they look at their indicative share in the overall market. The analysis at hand also contains the projections for the provinces of Punjab, Sindh, Khyber Pakhtunkhwa and Balochistan for public, private and commercial sector till 2030 based on the method mix. A variety of data sources have been tapped into which have been adequately referenced in the footnotes.

Pharmaceutical Industry in Pakistan:

The pharmaceutical sector in the country is a sizeable industry with an annual turnover of more than PKR 336 billion (\$3.2 billion) and a double-digit annual growth rate of 15%¹⁰. Currently, the industry has approximately 759 pharmaceutical manufacturing units including those operated by 25 multinational organizations. According to Pakistan Pharmaceutical Manufacturers' Association, their industry meets around 70% of the country's demand¹¹ of medicines.

Presently, only a few pharmaceutical industries including ZAFA Pharmaceutical, Karachi and HENSEL Pharmaceutical, Lahore are producing 3-month injectable (Depot Medroxyprogesterone Acetate), combined oral pill (COC), and emergency contraceptive pill (ECP). Unfortunately, no industry is producing condoms, intra-uterine devices (IUDs), and implants (single rod and two rod), which are being imported to meet the contraceptive requirements.

Cost Benefits - Local vs. International procurement:

An analysis was conducted by the project, whereby those years procurement trends were studied, during which the country was having a mix of USAID donated and provincially procured contraceptives. The three-year time frame i.e 2014-15, 2015-16 and 2016-17 was selected.

During three years of local contraceptive procurement (2014-15, 2015-16 and 2016-17), the Punjab, Sindh, Khyber Pakhtunkhwa and Balochistan provinces procured contraceptives including those of three products being manufactured in Pakistan. In order to have cost comparison between locally procured three commodities (3- months injection, oral contraceptive pills and emergency contraceptive pills) visà-vis international market prices, below tables depict year-wise as well as total cost savings which is PKR 556.68 m (\$5.30m):

Buo du sta	Punjab (2014-15)												
Products	International Market ¹²	Local Market ¹³	Savings										
DMPA	378,730,296	315,608,580	63,121,716										
COC	387,920,790	277,758,769	110,162,020										
ECP	5,233,694	1,811,490	3,422,204										
Total	771,884,779	595,178,839	176,705,940										

Year 2014-15: Savings - PKR 176.7 m

Year 2015-16: Savings- PKR 150 m

<u>e</u> p	P	unjab (2015-16)	ŀ	KPK (2015-16)		Sindh (2015-16)					
Pro duct s	Intl. Market	Local Market	Savings	Intl. Market	Local Market	Savings	Intl. Market	Local Market	Savings			
DMPA	76,889,820	65,447,882	11,441,938	91,206,444	77,634,057	13,572,388	169,342,068	144,142,356	25,199,713			
COC	37,040,693	26,588,292	10,452,401	91,840,902	65,600,645	26,240,258	181,165,345	129,403,798	51,761,547			
ECP	37,040,693	26,588,292	10,452,401	176,876	77,988	98,888	1,304,015	551,964	752,051			
Total	150,971,205	118,624,466	32,346,739	183,224,222	143,312,689	39,911,533	351,811,428	274,098,117	77,713,311			

Year 2016-17: Savings- PKR 230 m

-	P	unjab (2016-17)			KPK (2016-17)			Sindh (2016-17)		Balochistan (2016-17)				
Pr od uct	Intl. Market	Local Market	Savings	avings Intl. Market		Savings	Intl. Market	Local Market	Savings	Intl. Market	Local Market	Savings		
DMPA	119,943,180	102,094,493	17,848,688	91,206,444	77,634,057	13,572,388	214,210,080	182,333,580	31,876,500	29,464,615	25,080,000	4,384,615		
COC	171,972,347.4	123,443,995	48,528,352	91,840,902	65,924,598	25,916,304	229,174,142	164,504,190	64,669,952	39,727,845	28,517,165	11,210,679		
ECP	12,675,029.85	4,023,819	8,651,211	176,876	56,151	120,725	1,649,545	523,665	1,125,880	2,835,000	900,000	1,935,000		
Total	304,590,557	229,562,307	75,028,250	183,224,222	143,614,806	39,609,416	445,033,767	347,361,435	97,672,332	72,027,460	54,497,165	17,530,295		

¹⁰ http://www.ppma.org.pk/wp-content/uploads/2017/09/Final-Report-Pharma-Industry_August-10.pdf

¹¹ http://www.ppma.org.pk

¹² International rates have been taken from USAID Contraceptive and Condom Catalog 2013-14

¹³ Local rates are actual rates of locally manufactured products procured by provinces

Situation analysis – contraceptive manufacturing in Pakistan

i i ovinciai Savin	83		
Province ¹⁴	2014-15	2015-16	2016-17
Punjab	176,705,940	32,346,739	75,028,250
Sindh		77,713,311	97,672,332
KP		39,911,533	39,609,416
Balochistan			17,530,295
Total	176,705,940	149,971,583	229,840,293

Provincial Savings

The savings achieved through local procurement of DMPA, COC, and ECP can afford the provincial governments to re-allocate these resources to other components of the supply chain, including transportation from Central Warehouse to districts and SDP-level stores as well as robust monitoring.

In view of the cost savings achieved through local procurement of DMPA, COC, and ECP, enhancing the pharmaceutical industry's capacity to manufacture condoms, IUDs, and implants would further contribute towards cost savings.

The federal and provincial governments of Pakistan are cognizant of the whole gamut of challenges encountered by provinces in procuring internationally manufactured contraceptives during the last few years i.e. delays in international procurement owing to increased lead time, payment modalities to international manufacturers, transfer of huge foreign exchange, and finally non-existence of WHO prequalified firm and testing laboratories in Pakistan.

The potential benefits of local manufacturing of contraceptives include:

- Increased product availability, leading to improved CPR
- Efficient and timely procurement by decreased procurement timelines and procedures due to local procurement
- More efficiently/expediently meeting emergency requirements
- Increased efficiency and quality of locally manufactured products
- Improved pricing controls as Drug Regulatory Authority of Pakistan (DRAP) has full control over drugs pricing in the country
- Easier product recalls
- Increased export of pharmaceutical products and boost to the local economy

There are multiple factors influencing the investment in contraceptives production, as it is capitalintensive and enjoys significant and increasing returns to scale i.e. unit production costs decrease as the volume of production increases. Hence, the production volumes must be sufficient to keep the costs – and by extension price to consumers/buyers – low enough to be competitive in the market.

As per Pakistan Customs Tariff (PCT) Code number 9927 regarding Contraceptives and accessories thereof, all pharmaceutical raw materials if imported for manufacture of contraceptives in accordance with the input/output ratios determined by the Directorate of Input Output Co-efficient Organization will be zero-rated. However, there is an applicability of 17% sales tax.

- 3% duty on Chemical contraceptive preparations based on hormones, spermicides
- 3% duty on Coils of plastics (contraceptives and accessories therefor)
- 3% duty on Sheath contraceptives

¹⁴ Sindh and KP couldn't procure contraceptives in 2014-15 and Balochistan in 2014-15 and 2015-16

Situation analysis – contraceptive manufacturing in Pakistan

METHODOLOGY

It was agreed that GHSC-PSM project would undertake a desk review of the existing family planning procurement practices, including method mix, quantities ordered, and consumption over the past 10 years. PPW obtained data on the prescribed format from all provinces and shared contraceptives procurement and consumption data from 2007 till 2010 with the project (Annexure-III).

The GHSC-PSM project team extracted country wide procurement and consumption data from 2010 onwards from USAID supported annual contraceptive procurement tables (2010-2014) and contraceptive LMIS respectively. The project further worked on the data and generated projection of the demand including method mix till 2030 in view of Pakistan's FP2020 commitments, and National Health Vision-2025 and SDG-3 targets. The latest Pakistan Demographic and Health Survey was conducted in 2017-18. It is believed that the reliability of the demographic data alone to forecast business, without undertaking other important variables, would be unrealistic. Hence the project used forecast modelling based on all possible factors operating in the ecology of Pakistan. The methodology included the demographics, logistics and method mix.

While carrying out the analysis of the data, it was observed that over the years, data has shown fluctuating trends in terms of consumption of contraceptives. There may be different factors attributable to the fluctuation which include but are not limited to a shift from short-acting to long acting methods, promotions, and accessibility trends.

In view of the above, different forecast growth factors have been applied for different FP products. For accuracy purposes, more recent LMIS consumption data trends have been selected for extrapolation (July 2016-June 2019). It is pertinent to note that based on consumption trends, growth factors for method mix have been estimated leading to projections till 2030.

Once the factors were accounted for and a forecast for 2020-21 developed, then a flat 10% yearly increase was used for demand projections till 2030. This 10% annual increase will cater to the yearly population growth and the gradual improvements that would be registered in reporting rate of contraceptives use (currently the reporting rate of DOH and other stakeholder hovers around 60% and is likely to improve in the years to come.)

Similarly, analysis of the data for private sector was carried out and it has been observed that the trends for consumption have a tendency to fluctuate¹⁵. The data is not representative of the entirety of the private sector as it mainly focuses three organizations, Greenstar Social Marketing, Marie Stope Society, and Family Planning Association of Pakistan, who are reporting into the LMIS. There may be different factors attributable to the fluctuation which include but are not limited to a shift from short-acting to long acting methods, promotions of any method by private sector stakeholders, and accessibility trends which cover different options of product availability for FP clients.

The costing for the projected demands has been carried out on the basis of the unit costs of Punjab's procurement of contraceptives for 2017/18, and a 5% yearly inflation in prices (calculated on recent years' inflation) has been factored into arrive at the final cost. The highly diverse and disorganized structure of the private and commercial market operators poses a serious challenge to obtain accurate data for future projections. However, we have used PDHS to obtain our estimates which are given below. The table below contains the demand projections through 2030.

¹⁵ The analysis has been done based on active reporting years

Situation analysis – contraceptive manufacturing in Pakistan

PUBLIC SECTOR CONTRACEPTIVE PROJECTION WITH COSTING (2020-21 TO 2029-30)

				Na	ational P	ublic Sect	or* Con	traceptiv	ves Fore	cast with	o Cost f	or the Pe	eriod 20	20-21 to	2029-30)				
					Rational	e for Fore	ecast / P	rojection	s (base	d on July	2016 -	June 201	9 Consi	umption	trend)					
Products	Con	dom	P	ОР	С	OC	E	СР	Copper-T-380A		Mul	tiload	2-Mo	nth Inj	3-Mo	onth Inj	Imp	lanon	Ja	delle
I-yr AVG	G 20.254.187 11.932		.932	1.06	5.080	166	5.098	98	.081	12	.077	23	.341	398.255		2,013		4.805		
3-month	-, -	,		, -	,	- ,		,		,		,		,-		-,		,		,
AVG	11.72	2.544	5.4	424	834	1.016	6.	912	68	,862	2	290	ç	34	29	6.993		,392	3	3,597
% growth	,/2	2,311	5,	121		1,010		/12		,002				51		0,775		,572		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
l yr to 3-																				
month	40	19/	E.	4 5%	n	1.7%	01	5.8%	2	9.8%	0	7.6%	0	6.0%		5.4%		0.9%	-	25.1%
	-42.1% -54.5%		T.J /o	-2	1./ /0	-9:	J.0 <i>/</i> 0	-2	7.0/0	-9	/.0/6	-9	5.0 %	-2	J.T/0	-3	0.7/0	-2	.J.1 /o	
forecast																				
growth		~~				<i></i>														
factor	١.	03	I.	.03	I	.06	1.03		I	1.05		1.03		1.03		1.05		1.05		1.10
l-yr	yr 🔰																			
avg*growth																				
factor		51,813	12,290		1,128,985		171,081		102,985		12,440		24,041		418,168		2,113		5,286	
Year	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)
2020 -21	274,786,190	626,655,746	161,876	6,183,908	16,208,279	381,829,275	2,253,430	23,477,641	1,437,049	61,385,511	163,851	18,967,760	316,668	54,987,421	5,835,123	482,974,190	29,491	34,276,606	84,800	107,983,128
2021 -22 2022 -23	283,029,776 291,520,669	677,728,190 732,963,037	166,732	6,687,897 7,232,960	17,180,776	424,975,983 472,998,269	2,321,033 2,390,664	25,391,069 27,460,441	1,508,902 1,584,347	67,677,525 74,614,472	168,766 173,829	20,513,632 22,185,493	326,168 335,953	59,468,896 64,315,611	6,126,879	532,479,045 587,058,147	30,966 32,514	37,789,958 41,663,429	93,280 102,608	124,720,512 144,052,192
2022 -23	300,266,289	792,699,525	176,886	7,232,960	18,211,623 19,304,320	526,447,073	2,390,664	29,698,467	1,584,347	82,262,455	173,829	23,993,611	335,953	69,557,333	6,433,223 6,754,884	647,231,607	34,140	41,003,429	112,869	166,380,282
2023 -24	309,274,278	857,304,536	182,192	8,459,976	20,462,579	585,935,592	2,402,304	32,118,892	1,003,504	90,694,357	184,415	25,949,090	346,032	75,226,256	7,092,628	713,572,846	35,847	50,642,158	124,156	192,169,225
2025 -26	318,552,506	927,174,856	187,658	9,149,464	21,690,334	652,146,314	2,612,343	34,736,582	1,834,079	99,990,528	189,948	28,063,941	367,105	81,357,196	7,447,259	786,714,063	37,639	55,832,979	136,571	221,955,455
2026 -27	328,109,082	1,002,739,606	193,288	9,895,145	22,991,754	725,838,848	2,690,713	37,567,613	1,925,783	110,239,557	195,646	30,351,152	378,118	87,987,807	7,819,622	867,352,255	39,521	61,555,859	150,228	256,358,551
2027 -28	337,952,354	1,084,462,884	199,086	10,701,600	24,371,259	807,858,638	2,771,435	40,629,374	2,022,072	121,539,112	201,516	32,824,771	389,462	95,158,814	8,210,603	956,255,861	41,497	67,865,335	165,251	296,094,126
2028 - 29	348,090,925	1,172,846,609	205,059	11,573,780	25,833,535	899,146,664	2,854,578	43,940,668	2,123,176	133,996,871	207,561	35,499,990	401,146	102,914,257	8,621,134	1,054,272,086	43,572	74,821,532	181,776	341,988,715
2029 - 30	358,533,652	1,268,433,608	211,211	12,517,043	27,383,547	1,000,750,237	2,940,215	47,521,832	2,229,335	147,731,550	213,788	38,393,239	413,180	111,301,769	9,052,190	1,162,334,975	45,751	82,490,739	199,954	394,996,966
Total Cost (PKR)	3,150,115,723	9,143,008,598	1,855,722	90,224,220	213,638,006	6,477,926,893	25,833,048	342,542,578	18,075,049	990,131,939	1,878,364	276,742,679	3,630,244	802,275,360	73,393,545	7,790,245,075	370,940	552,872,523	1,351,492	2,246,699,152
																	Total C	Cost (PKR)	28,712	2,669,016
																Total Co		in Millions		8,713
																Total Co	st (USD)	in Millions		6179
																I Utal CU		III FIIIIOIIS	4	<u></u>

PRIVATE SECTOR CONTRACEPTIVE PROJECTION WITH COSTING (2020-21 TO 2029-30)

						Natio										e Perio				30						
							Ratio	nale fo	<mark>r Fore</mark>	ecast / F	roject	tions (<mark>l</mark>	based o	on 2012	- 2016	Consur	<mark>mptio</mark>	n trend)							
Produc ts	Con	dom	Р	РОР СОС		ECP		Cop 3	per-T- 80A	Mul	tiload	2-Mc	onth Inj	3-Mo	onth Inj	Imp	olanon	Ja	delle	Fen	nplant	I-Ma	nth Inj	Safe	e Load	
5-yr AVG	11,51	1,421	4,	509	11	5,613	188	188,816		26.094		33.031		44,344		50.463		542	432		207		13,899		2,691	
l Yr AVG	10.39	10,398,761 10,118		.118	82,084		19	,461	35	6.634	13	3,245	27	7,323	4	.568		23		548		92	9,858		5.032	
% growth				, -	-	,		, -		,		, -				<u>,</u>		-								
5 to I Yr	-9.7%		12	124.4%		9.0%	1	4%	30	6.6%	-5	9.9%	-3	8.4%	-1	7.6%	-9	5.8%	4	9.8%	-5	5.5%	-2	9.1%	80	6. 9 %
forecast growth	1																						_			
factor 5 yr	I.	10		1.05		.10		.10		.10		.01		1.02		.10		.05	!	.10		.01		.01		.01
avg*gro wth			4.735				207.698		20	702		33.362		45.231		55.510		569	475		209		14.038		2.718	
factor		Cost(PKR	Quant	Cost(P	Quantit	7,175 Cost(PKR	Quantit	Cost(PK	Quanti	3,703 Cost(PK	Quanti	Cost(PK	4: Quanti	Cost(PKR	Quantit	Cost(PKR	Quant	Cost(PK	Quant	Cost(PK	Quant	Cost(P	Quanti	Cost(PK	Quant	,/18 Cost(PK
Year	Quantity 203,156,5) 463,302,8	ity	KR) 2,523,99	у 2,040,3) 48,066,46	у 3,332,2	R) 34,717,6	ty 460,51	R) 19,671,4	ty 414,32	R) 47,963,6	ty 578,58) 100,467,3	у) 73,714,40	ity	R) 9,223,21	ity	R) 9,713,98	ity	KR) 3,018,51	ty 174,34	R) 14,430,6	ity	R) 39,237,7
2020 -21	60 223,472,2	52 535,114,7	66,070	9 2,782,70	75 2,244,4	9 55,516,77	73 3,665,5	99 40,098,9	3 506,56	59 22,720,5	8 418,47	25 50,865,4	3 590,15	81 107,600,5	890,591	7 85,140,14	7,936	2 10,168,5	7,628	7	2,597	6 3,201,13	6 176,08	41 15,303,6	33,760	96 41,611,6
2021 -22	16	94 618,057,5	69,374	9 3,067,93	12	2 64,121,87	00 4,032,0	43 46,314,2	5	35	I 422,65	24	5 601,95	65 115,240,2	979,650 1,077,6	0 98,336,86	8,332	91	8,391	55	2,623	7 3,394,80	9	95	34,098	83
2022 -23	37	87	72,843	6	53	2	50	79	Ĺ	18	6	82	8	05	15	I	8,749	72	9,230	01	2,649	5	0	69	34,439	90
2023 -24	270,401,3 81	713,856,5 13	76,485	3,382,40 0	2,715,7 39	74,060,76 2	4,435,2 55	53,492,9 92	612,94 3	30,309,7 62	426,88 2	57,206,3 21	613,99 7	123,422,2 59	1,185,3 77	113,579,0 75	9,186	12,359,9 86	10,153	14,967,3 00	2,676	3,600,19 I	179,62 9	17,211,4 58	34,783	46,799,0 06
2024 -25	297,441,5 19	824,504,2 72	80,309	3,729,09	2,987,3 12	85,540,18	4,878,7 80	61,784,4 06	674,23 8	35,007,7 75	431,15	60,667,3 03	626,27 7	132,185,2 40	1,303,9 15	131,183,8 32	9.646	13,626,8 85	11,169	17,287,2	2.703	3,818,00	181,42	18,252,7 51	35.131	49,630,3 46
	327,185,6	952,302,4	84.325	4,111,32	3,286,0	98,798,90	5,366,6	71,360,9	741,66	40,433,9	435,46	64,337,6	638,80	141,570,3	1,434,3	151,517,3	10,128	15,023,6	12,286	19,966,7	2,730	4,048,99	183,23	19,357,0	35,482	52,632,9
2025 -26	71 359,904,2	34 1,099,909,		4,532,73	44 3,614,6	8 4, 2,7	58 5,903,3	82,421,9	815,82	80 46,701,2	439,81	75 68,230,1	651,57	92 151,621,8	06 1,577,7	26 175,002,5		41 16,563,5	,	52 23,061,5	,	2 4,293,95	185,07	42 20,528,1	,	82 55,817,2
2026 -27	38 395,894,6	312	88,541	9 4,997,34	48 3,976,1	39 131,800,2	24 6,493,6	42 95,197,3	8 897,41	47 53,939,9	7 444,21	04 72,358,0	9 664,61	90 162,387,0	37 1,735,5	11 202,127,9	10,634	64 18,261,3	13,514	99 26,636,1	2,757	6 4,553,74	2 186,92	43 21,770,0	35,837	77 59,194,2
2027 -28	62	255	92,968	5	13	13	57	43	Ó	40 62,300,6	6 448,65	26	0	44	10	00	11,166	29	14,866	47	2,784	0 4,829,24	2	96 23,087,1	36,195	22
2028 -29	435,484,1 28	1,467,306, 520	97,616	5,509,57 3	4,373,7 24	152,229,2 47	7,143,0 22	109,952, 931	987,15 I	31	8	76,735,6 86	677,90 3	173,916,5 24	1,909,0 61	233,457,7 25	11,725	20,133,1 15	16,352	30,764,7 50	2,812	4,829,24 I	188,79 2	87	36,557	62,775,4 73
2029 - 30	479,032,5 41	1,694,739, 030	102,49	6,074,30 4	4,811,0 97	175,824,7 80	7,857,3 25	126,995, 635	1,085,8 67	71,957,2 29	453,14	81,378,1 95	691,46	186,264,5 97	2,099,9 68	269,643,6 72	12,311	22,196,7 60	17,988	35,533,2 86	2,840	5,121,41	190,68	24,483,9 62	36,923	66,573,3 89
Total Cost (PKR)	3,237,792,	9,639,488, 569	831,02 7	40,711,4	32,518, 317	1,000,071, 943	53,107, 844	722,337,	7,339,3 98	409,284, 776	4,334,7 86	633,685, 143	6,335,3 26	1,394,676, 096	14,193, 731	1,533,703, 448	99,813	148,767, 956	121,57	202,109, 409	27,172	39,879,9 91	1,824,0 44	190,654, 543	353,20	518,401 363
<u>`</u>																						1	Total Co	st (PKR)	16,473	,771,824
																						otal Cost	<u> </u>			,474
																					Тс	tal Cost ((USD) in	Millions	\$10	02.96

PUNJAB - PUBLIC SECTOR CONTRACEPTIVE PROJECTION WITH COSTING (2020-21 TO 2029-30)

					Ratio	nale for F	orecast	/ Project	ions (ba	<mark>ised on J</mark> u	ly 2016 ·	- June 20 I	9 Consu	imption t	rend)					
Products	Con	dom	Р	OP	C	oc	E	СР	Coppe	r-T-380A	Mul	tiload	2-Mo	nth Inj	3-Mc	nth Inj	Imp	lanon	Ja	delle
I-yr AVG	20,25	4,187		,932	1,06	5,080	166	5,098	98	3,081	12	,077	23	,341	39	8,255	2,	013	4	,805
3-month										·		·								
AVG	11,72	2,544	5,	424	834	1,016	6,	912	68	3,862	2	290	9	34	29	6,993	Ι,	392	3.	,597
% growth																				
yr to 3-																				
nonth	-42	.1%	-54	4.5%	-2	1.7%	-9	5.8%	-2	9.8%	-9	7.6%	-90	6.0%	-2	5.4%	-3	0.9%	-2	5.1%
forecast																				
growth																				
factor	1.0	03	I	.03	I	.06	Ι	.03	I	.05		.03		.03		.05		.05	l	1.10
-yr																				
avg*growt																				
n factor	20,86	1,813	12	,290	1,12	8,985	17	,08 I	10	2,985	12	,440	24	,041	41	8,168	2,	113	5.	,286
		Cost(PK	Quantit	Cost(PK	Quantit	Cost(PK	Quantit	Cost(PK	Quantit	Cost(PK	Quantit	Cost(PK	Quantit	Cost(PK	Quantit	Cost(PK	Quantit	Cost(PK	Quantit	Cost(P
Year	Quantity	R)	у	R)	у	R)	у	R)	у	R)	у	R)	у	R)	у	R)	у	R)	у	R)
2020 -21	141,537,456	322,779,177	83,379	3,185,221	8,348,595	196,673,436	1,160,701	12,092,913	740,198	31,618,566	84,397	9,769,954	163,110	28,323,038	3,005,567	248,771,375	15,191	17,655,267	43,679	55,620,1
2021 -22	145,783,580	349,085,680	85,881	3,444,816	8,849,511	218,897,535	1,195,523	13,078,486	777,208	34,859,469	86,928	10,566,205	168,003	30,631,366	3,155,846	274,270,441	15,950	19,464,932	48,047	64,241,3
2022 -23	150,157,087	377,536,163	88,457	3,725,569	9,380,481	243,632,956	1,231,388	14,144,382	816,068	38,432,565	89,536	11,427,351	173,043	33,127,822	3,313,638	302,383,161	16,748	21,460,088	52,851	74,198,7 85,699,5
2023 -24	154,661,800 159,301,654	408,305,360	91,111	4,029,202	9,943,310 10,539,909	271,163,480 301,804,953	1,268,330	15,297,150	856,872 899,715	42,371,903 46,715,023	92,222 94,989	12,358,680	178,235	35,827,739 38,747,700	3,479,320	333,377,435 367,548,622	17,585	23,659,746 26,084,871	58,137 63,950	
2024 -25	164,080,704	441,582,247	93,844 96,659	4,357,582 4,712,725	11,172,303	335,908,913	1,306,380 1,345,571	17,892,193	944,701	51,503,312	94,989	14,455,235	183,582 189,089	41,905,638	3,653,286 3,835,950	405,222,356	18,464	28,758,570	70,345	98,982,9 114,325,2
025 - 26 026 - 27	169,003,125	516,493,253	99,559	4,712,725	11,172,303	373,866,620	1,345,571	19,350,406	944,701	56,782,402	100,774	14,455,235	189,089	41,905,838	4,027,748	405,222,356 446,757,647	20,357	31,706,323	70,345	132,045,
026 - 27 027 - 28	174.073.219	558.587.453	102.546	5,096,813	12,553,200	416,113,548	1,385,938	20,927,464	1,041,533	62.602.598	100,774	16,907,453	200,605	45,320,947	4,027,748	446,757,647	21,375	31,706,323	85.118	152,512,
027 -28	179,295,415	604,112,330	102,348	5,961,447	13,306,392	463,134,379	1,470,342	22,633,053	1,041,555	69,019,364	105,797	18,285,410	206,623	53,009,295	4,440,592	543,036,712	21,373	38,539,234	93,630	176,152,
028 - 29	184,674,278	653,347,485	103,822	6,447,305	14,104,776	515,468,564	1,470,342	24,477,646	1,148,290	76,093,849	110,118	19,775,671	212,822	57,329,552	4,440,392	598,697,975	23,565	42,489,505	102,993	203,455,
otal Cost	1,622,568,3	4,709,400,34	100,771	0,777,303	14,104,778	3,336,664,38	1,514,452	24,477,040	1,140,270	70,075,047	110,110	17,113,011	212,022	37,327,332	4,002,021	4,012,616,02	23,305	42,407,303	102,773	1,157,234
PKR)	1,022,500,5	4,707,400,34 7	955,849	46,472,884	9	5,550,864,58	13,306,142	176,437,561	9,310,131	509,999,051	967,512	142,545,209	1,869,874	413,237,702	37,803,703	9	191,065	284,774,757	696,129	6
																	Total	Cost (PKR)	14,789	,382,509
																Total	Cost (PKR) in Millions	14	,789
-																	Cost (USD			5 92

PUNJAB - PRIVATE SECTOR CONTRACEPTIVE PROJECTION WITH COSTING (2020-21 TO 2029-30)

						Punja	lb Priva	ite Sect	tor* C	ontrace	ptives	Foreca	lst wit	h Cost f	for the	Period	2020	-21 to 2	2029-3	0						
							Ratio	nale fo	<mark>r Fore</mark>	cast / P	rojecti	<mark>ions (b</mark> a	ised or	י 2012 -	2016	Consun	n <mark>ptio</mark> r	<mark>n trend</mark>))							
Produc ts	Con	dom	P	ОР	C	ос	E	СР		per-T- 30A	Mul	tiload	2-Mo	nth Inj	3-Mo	onth Inj	Imp	lanon	Ja	delle	Fen	nplant	I-Mo	nth Inj	Safe	Load
5-yr AVG	11,51	1.421	4.	509	115	5.613	188	.816	26	.094	33	.031	44	.344	50).463	5	542		432		207	13	.899	2.	.691
l Yr AVG	10,39	,	10	,118	82	.084	191	,461	35	,634	13	,245	27	,323	41	,568		23		548		92	9	858	5	.032
% growth	10,57	0,701	10	,110		,00-1	171	,-101		,054		,2-13	27	,525		,500		25		5-10		72	,	050	Э,	002
5 to 1 Yr	-9	7%	12	4.4%	-29	9.0%	1.	4%	34	5.6%	-5'	9.9%	-3	8.4%	-1	7.6%	-9	5.8%	4	9.8%	-5	5.5%	-2	9.1%	84	6.9%
forecast				1.170				170										5.070				5.570		,,0		
growth factor	١.	10	1	.05	1	.10	1.	10		.10		.01	1	.02	I	.10		.05		.10		.01		.01	1	.01
5 yr avg*gro wth																										
factor	12,66	2,563	4,	735	127	,175	207	,698	28	,703	33	,362		,231	55	5,510	5	569		475	2	209	14	,038	2,	718
Year	Quantity	Cost(PKR)	Quanti ty	Cost(PK R)	Quantit y	Cost(PK R)	Quantit y	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)								
2020 -21	104,642,31	238,639,02 0	34,032	1,300,06 6	1,050,96 I	24,758,1 79	1,716,39 4	17,882,4 66	237,20 2	10,132,4 17	213,41	24,705,2 06	298,01 8	51,748,9 52	458,72 8	37,968,9 74	4,087	4,750,71 0	3,929	5,003,50 I	1,338	1,554,78 4	89,802	7,432,96 5	17,389	20,210,6 88
2021 -22	115,106,54 5 126,617,20	275,628,06 8 318,350,41	35,733	1,433,32 3 1,580,23	1,156,05 7 1,271,66	28,595,6 97 33,028,0	1,888,03 4 2,076,83	20,654,2 49 23,855,6	260,92 2 287,01	11,702,9 42 13,516,8	215,54 7 217,70	26,199,8 71 27,784,9	303,97 8 310,05	55,423,1 28 59,358,1	504,60 0 555,06	43,854,1 65 50,651,5	4,292	5,237,65 7 5,774,51	4,322	5,779,04 4 6,674,79	1,351	1,648,84 8 1,748,60	90,700	7,882,66 0 8,359,56	17,563	21,433,4 34 22,730,1
2022 -23	0	9 367,694,73	37,520	9	1,271,00 2 1,398,82	30 38,147,3	2,070,03	57 27,553,2	5 315,71	98	217,70	63 29,465,9	8 316,25	70 63,572,6	0 610,56	60 58,502,5	4,506	6,366,40	4,754	5 7,709,38	1,365	4	91,607	8,865,31	17,739	57 24,105,3
2023 -24	9 153,206,81	3 424,687,41	39,396	3 1,920,79	8 1,538,71	75 44,060,2	2,512,97	84 31,824,0	6 347,28	17 18,031,8	9 222,07	54 31,248,6	9 322,58	00 68,086,2	7 671,62	52 67,570,4	4,732	5 7,018,96	5,230	9 8,904,34	1,378	4 1,966,58	92,524	4 9,401,66	17,916	32 25,563,7
2024 -25	1 168,527,49 3	7 490,513,96 7	41,366	0 2,117,67	I 1,692,58 2	18 50,889,5 52	3 2,764,27 0	43 36,756,7 70	8 382,01 7	79 20,826,8 21	8 224,29 9	44 33,139,1 87	4 329,03 6	55 72,920,3 79	3 738,78 5	47 78,043,8 67	4,968	2 7,738,40 6	5,753 6,328	4 10,284,5 17	1,392 1,406	5 2,085,56 3	93,449 94,383	6 9,970,46 7	18,095	04 27,110,3 08
2026 -27	185,380,24 2	566,543,63 2	45,606	2,334,73 2	I,861,84	58,777,4 33	3,040,69 7	42,454,0 69	420,21 8	24,054,9 78	226,54 2	35,144,1 08	335,61 7	78,097,7 26	812,66 4	90,140,6 66	5,478	8,531,59 2	6,961	11,878,6 18	1,420	2,211,74 0	95,327	10,573,6 80	18,459	28,750,4 82
2027 -28	203,918,26	654,357,89 5 755 792 24	47,886	2,574,04 2	2,048,02	67,887,9 35 78,410 F	3,344,76 7	49,034,4 50	462,24 0	27,783,4 99	228,80 7	37,270,3 26	342,32 9	83,642,6 64	893,93 0	104,112, 469	5,752	9,406,08 0	7,657	13,719,8 03	1,434	2,345,55 0	96,280	11,213,3 87	18,644	30,489,8 86
2028 -29	224,310,09 755,783,36 2,837,88 2,252,82 78,410,5 3,679,24 56,634,7 508,46 32,089,9 231,09 39,525,1 349,17 89,581,2 983,32 120,249, 10,370,2 15,846,3 2,487,45 11,891,7 32,334,5 -29 3 8 50,280 1 7 65 3 90 4 42 6 81 6 94 3 902 6,039 04 8,423 73 1,449 6 97,243 97 18,830 24 246,741,10 872,929,79 3,128,76 2,478,11 90,564,2 4,047,16 65,413,1 559,31 37,063,8 233,40 41,916,4 356,15 95,941,5 1,081,6 138,888, 11,433,1 18,302,5 2,637,94 12,611,2 34,290,7																									
2029 - 30 Total	2	0	52,794	4	0	02	7	82	0	83	7	54	9	65	56	637	6,341	49	9,265	61	1,463	7	98,216	51	19,018	63
Cost (PKR)	1,667,728, 984	4,965,128, 308	428,04 7	20,969,7 21	16,749,6 04	515,119, 187	27,354,9 02	372,062, 961	3,780,3 93	210,815, 275	2,232,7 71	326,399, 893	3,263,2 13	718,372, 735	7,310,9 37	789,983, 240	51,412	76,627,6 83	62,623	104,102, 945	13,996	20,541,4 71	939,53 2	98,202,7 48	181,92 9	267,019, 278
																					То	tal Cost (st (PKR) Millions		345,445 485
																					То	tal Cost (USD) in	Millions	\$5	3.03

				Sir	ndh Pub	lic Sector [:]	* Contr	aceptive	es Fored	ast with	Cost fo	or the P e	eriod 2	020-21 to	2029-30	0				
				F	lational	e for Fore	ast / Pr	ojection	s (base	d on July	2016 -	June 20	l 9 Con	sumptio	n trend)					
Products	Со	ndom	Р	OP	C	OC	E	СР	Coppe	r-T-380A	Mul	tiload	2-M	onth Inj	3-Mo	nth Inj	Imp	olanon	Ja	delle
I-yr AVG	20,2	54,187		,932	1,0	65,080	166	5,098	98	,081	12	,077	2	3,341	398	8,255	2	,013	4	,805
3-month																		-		·
AVG	11,7	22,544	5,	424	83	4,016	6,	912	68	.862	2	290		934	290	6,993	I	,392	3	.597
% growth		·	,			,	,			,						<i>'</i>		, 		,
l yr to 3-																				
month	-4	2.1%	-54	4.5%	-2	1.7%	-9	5.8%	-2	9.8%	-9	7.6%	-9	6.0%	-2	5.4%	-3	0.9%	-2	25.1%
forecast																				
growth																				
factor	I	.03	1	.03		.06	1	.03		.05		.03		1.03	1	.05		.05		1.10
l-yr																				
, avg*growth																				
factor	20,8	61,813	12	,290	1,12	28,985	17	1.081	10	2,985	12	.440	24	4,041	418	8,168	2	,113	5	.286
Year	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)
2020 -21	68,388,798	155,962,107	40,288	1,539,051	4,033,917	95,029,685	560,834	5,843,116	357,653	15,277,622	40,779	4,720,697	78,812	13,685,272	1,452,246	120,202,636	7,340	8,530,763	21,105	26,874,845
2021 -22	70,440,462	168,673,019	41,496	I,664,484	4,275,952	105,768,040	577,659	6,319,330	375,535	16,843,578	42,003	5,105,434	81,177	14,800,621	1,524,858	132,523,406	7,707	9,405,166	23,216	31,040,446
2022 -23	72,553,676	182,419,870	42,741	1,800,139	4,532,509	117,719,828	594,988	6,834,356	394,312	18,570,045	43,263	5,521,526	83,612	16,006,872	1,601,101	146,107,055	8,092	10,369,196	25,537	35,851,715
2023 -24	74,730,286	197,287,089	44,023	1,946,851	4,804,460	131,022,169	612,838	7,391,356	414,028	20,473,474	44,560	5,971,531	86,120	17,311,432	1,681,156	161,083,028	8,497	11,432,038	28,091	41,408,731
2024 -25	76,972,195	213,365,987	45,344	2,105,519	5,092,728	145,827,674	631,223	7,993,751	434,729	22,572,005	45,897	6,458,211	88,704	18,722,314	1,765,214	177,594,038	8,922	12,603,822	30,900	47,827,084
2025 -26	79,281,360	230,755,315	46,704	2,277,119	5,398,291	162,306,201	650,160	8,645,242	456,466	24,885,636	47,274	6,984,555	91,365	20,248,182	1,853,474	195,797,427	9,368	13,895,714	33,990	55,240,282
2026 -27	81,659,801	249,561,873	48,105	2,462,704	5,722,189	180,646,801	669,665	9,349,829	479,289	27,436,414	48,692	7,553,796	94,106	21,898,409	1,946,148	215,866,664	9,836	15,320,025	37,389	63,802,526
2027 -28	84,109,595	269,901,166	49,549	2,663,415	6,065,520	201,059,890	689,755	10,111,840	503,253	30,248,646	50,153	8,169,430	96,929	23,683,129	2,043,455	237,992,997	10,328	16,890,327	41,128	73,691,918
2028 - 29	86,632,883	291,898,111	51,035	2,880,483	6,429,451	223,779,658	710,447	10,935,955	528,416	33,349,132	51,658	8,835,239	99,837	25,613,304	2,145,628	262,387,279	10,844	18,621,586	45,240	85,114,165
2029 - 30	89,231,870	315,687,807	52,566	3,115,242	6,815,218	249,066,759	731,761	11,827,235	554,837	36,767,418	53,208	9,555,311	102,832	27,700,789	2,252,909	289,281,975	11,386	20,530,298	49,764	98,306,861
Cost (PKR)	784,000,927	2,275,512,344	461,852	22,455,007	53,170,235	1,612,226,703	6,429,330	85,252,010	4,498,517	246,423,971	467,487	68,875,729	903,495	199,670,324	18,266,188	1,938,836,504	92,320	137,598,936	336,359	559,158,574
			•			• · ·	•	•				-			-		Total C	Cost (PKR)	7,146	,010,103
																Total Co	ost (PKR)	in Millions	7	,146
																Total Co	st (USD)	in Millions		\$45

SINDH - PUBLIC SECTOR CONTRACEPTIVE PROJECTION WITH COSTING (2020-21 TO 2029-30)

SINDH - PRIVATE SECTOR CONTRACEPTIVE PROJECTION WITH COSTING (2020-21 TO 2029-30)

						Sind										Period)						
							Rati	onale fo	1		ojectio	ons (ba	sed or	<u>12012 -</u>	2016	Consun	nptior	n trend)							
Produc ts	Con	dom	P	OP	с	ос	E	СР		per-T- 30A	Mult	tiload	2-Mo	onth Inj	3-Mo	onth Inj	Imp	lanon	Jac	delle	Fen	nplant	I-Mo	nth Inj	Safe	e Load
5-yr AVG	115	1,421	4	509		5,613	100	.816	24	.094	22	.031	11	,344	50),463		42		32		207	12	.899		.691
l Yr	11,51	1,721	т,.	507	11.	5,015	100	,010	20	,074	33	,031		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	50	,105		2		152		.07	13	,077	<u></u> ,	071
AVG	10,39	98,761	10	118	82	,084	191	,461	35	,634	13	,245	27	,323	41	,568	:	23	é	648		92	9,	858	5,	,032
% growth 5																									1	
ol Yr	-9	.7%	124	1.4%	-2	9.0%	Ι.	4%	36	5.6%	-59	9.9%	-3	8.4%	-1	7.6%	-9	5.8%	49	9.8%	-5	5.5%	-29	9.1%	86	6.9%
orecast																										
growth factor	1	10	I	.05		.10	1	10		.10	I	.01	1	.02		.10	1	.05	ı	.10	1	.01	1	.01	1 1	1.01
5 yr																									· · ·	
avg*gro wth																									1	
factor	12,66	52,563	4,	735	12	7,175	207	.698	28	,703	33	,362	45	.231	55	5,510	5	69	4	75	2	209	14	.038	2.	,718
Year	Quantity	Cost(PKR)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quantit v	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(P R)
2020 -21	50,561,61	115,306,83	16,444	628,173	507,80	11,962,78 5	829,336	8,640,542	114,61	4,895,833	103,11	11,937,18 9	143,99	25,004,32	221,65	18,346,04	1,975	2,295,47	1.899	2,417,61	646	751,248	43,391	3,591,49	8,402	9,765,50
2021 -22	55,617,77	133,179,39	17,266	692,560	558,58	13,817,01	912,270	9,979,826	126,07	5,654,688	104,14	12,659,38	146,87	26,779,63	243,81	21,189,68	2,074	2,530,75	2,088	2,792,34	653	796,699	43,825	3,808,78	8,486	10,356,3
-	61,179,55	153,822,19	,	,	614,44	15,958,65	1,003,49	11,526,70	138,68		105,19	13,425,28	149,81	28,680,98	268,19	24,474,08		2,790,16	, í	3,225,16		í í		4,039,21	,	10,982,
2022 -23	67,297,50	7 177,664,63	18,129	763,548	8 675,89	4 18,432,24	7	0 13,3 3,33	152,54	6,531,164	106,24	2 14,237,51	5	7 30,717,33	295,01	2 28,267,56	2,177	3,076,15	2,297	2 3,725,06	659	844,899	44,263	6 4,283,58	8,571	5
2023 -24	7 74,027,25	7 205,202,65	19,036	841,811	3 743,48	5 21,289,24	6 1,214,23	8 15,376,90	9 167,80	7,543,495	3 107,30	I 15,098,88	2	7 32,898,26	7 324,51	5 32,649,03	2,286	3 3,391,45	2,527	2 4,302,44	666	896,016	44,706	8 4,542,74	8,657	8
2024 -25	7 81,429,98	6 237,009,06	19,987	928,097 1,023,22	2 817,83	3 24,589,07	I 1,335,65	5	4	8,712,736 10,063,21	5	I 16,012,36	8	8 35,234,04	8 356,97	7 37,709,63	2,401	8 3,739,08	2,780	7 4,969,32	673	950,225 1,007,71	45,153	5 4,817,58	8,743	2
2025 -26	3 89,572,98	8 273,745,47	20,987	7	899,61	6 28,400,38	4	6 20,513,17	5 203,04	I I I 1,623,00	8	3	5	5 37,735,66	0 392,66	8 43,554,63	2,521	3 4,122,33	3,058	6 5,739,57	679	3	45,605	I 5,109,04	8,831	9
2026 -27	Í	3	22,036	8	4	3	0	6	3	8	2	1	5	2	7	2	2,647	9	3,363	2	686	0	46,061	5	8,919	6
2027 -28	98,530,27 9	2	23,138	1,243,73 9	989,57 5	32,802,44 2	1,616,14 2	23,692,71 8	223,34 8	13,424,57 4	110,55 6	18,008,46 8	165,40 8	40,414,89 4	431,93 4	50,305,60 0	2,779	4,544,87 8	3,700	6,629,20 5	693	1,133,33 5	46,521	5,418,14 2	9,008	14,732,2 0
2028 -29	108,383,3 07	365,183,30 5	24.295	1,371,22 2	1,088,5 33	37,886,82	1,777,75 6	27,365,09 0	245,68 2	15,505,38 4	111,66 2	19,097,98 I	168,71 6	43,284,35	475,12 7	58,102,96 8	2,918	5,010,72 8	4.070	7,656,73	700	1,201,90 2	46,986	5,745,94 0	9.098	15,623,
2029 - 30	119,221,6	421,786,71	25.509	1,511,77	1,197,3 86	43,759,27 8	1,955,53 I	31,606,67	270,25	17,908,71 8	112,77 9	20,253,40 8	172,09	46,357,54 0	522,64 0	67,108,92 8	3,064	5,524,32 8	4.477	8,843,52 6	707	1,274,61	47,456	6,093,56 9	9,189	16,568,
otal Cost	805,821,8	2,399,076,	206,82	10,132,2	8,093,1	248,897,9	13,217,4	179,775,3	1,826,6	101,862,8	1,078,8	157,711,5	1,576,7	347,107,0	3,532,5	381,708,1	-,	37,025,3	.,	50,300,9		9,925,33	453,96	47.450.1		129,019
PKR)	90	2,377,070,	6	58	60	45	82	00	30	11	42	84	36	42	36	75	24,842	59	30,258	98	6,762	4	8	10	87,906	52
																					.		otal Cos		<u> </u>	,992,96
																						otal Cost		Millions	4, \$2	,100

KHYBER PAKHTUNKHWA - PUBLIC SECTOR CONTRACEPTIVE PROJECTION WITH COSTING (2020-21 TO 2029-30)

			Khy	yber Pak	htunkh	wa Public	Sector	r* Contr	aceptiv	es Forec	ast wit	h Cost fo	or the F	Period 20	20-21 to	2029-30				
				Ra	tionale	for Fored	ast / Pi	rojectio	ns (bas	ed on Jul	y 2016	June 20	l 6 Cor	nsumptio	n trend)				
Products	Cor	ndom	Р	OP	C	OC	E	СР	Сорре	r-T-380A	Mul	tiload	2-Mc	onth Inj	3-Mo	onth Inj	Imp	lanon	Ja	delle
I-yr AVG	20,2	54,187		,932	1,06	5,080	166	5,098	98	.081	12	,077	23	3,341	39	8,255	2	,013	4	.805
3-month	,			,		,		,		,		,		,		,		·		,
AVG	11,72	22,544	5.	424	834	1,016	6,	912	68	.862	2	.90		934	29	6,993	1	,392	3	.597
% growth		,	,			<i>.</i>	,			,						<i>.</i>				,
l yr to 3-																				
month	-47	2.1%	-54	4.5%	-2	.7%	-9	5.8%	-2	9.8%	-9	7.6%	-9	6.0%	-2	5.4%	-3	0.9%	-2	5.1%
forecast				-		-		-		-	· · ·	-				-				
growth																				
factor	1	.03		.03	1.	.06	1	.03		.05		.03		.03		.05		.05		1.10
I-yr											-				-					
avg*growth																				
factor	20.86	61,813	12	.290	1.12	8.985	17	1.081	10	2.985	12	.440	24	1.041	41	8.168	2	.113	5	.286
Year	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)
2020 -21	39,993,769	91,206,640	23,560	900,037	2,359,035	55,573,360	327,976	3,417,054	209,155	8,934,353	23,848	2,760,663	46,089	8,003,147	849,273	70,294,501	4,292	4,988,790	12,342	15,716,409
2021 -22	41,193,582	98,639,981	24,267	973,390	2,500,577	61,853,150	337,815	3,695,544	219,613	9,850,124	24,563	2,985,658	47,472	8,655,403	891,737	77,499,688	4,507	5,500,141	13,576	18,152,453
2022 -23	42,429,390	106,679,140	24,995	1,052,722	2,650,611	68,842,555	347,949	3,996,731	230,594	10,859,762	25,300	3,228,989	48,896	9,360,819	936,324	85,443,406	4,732	6,063,906	14,934	20,966,083
2023 -24	43,702,271	115,373,490	25,745	1,138,518	2,809,648	76,621,764	358,388	4,322,465	242,123	11,972,888	26,059	3,492,151	50,363	10,123,725	983,140	94,201,355	4,969	6,685,456	16,427	24,215,826
2024 -25	45,013,339	124,776,429	26,517	1,231,308	2,978,227	85,280,024	369,139	4,674,746	254,230	13,200,109	26,841	3,776,762	51,874	10,948,809	1,032,297	103,856,994	5,217	7,370,715	18,070	27,969,279
2025 -26	46,363,740	134,945,708	27,313	1,331,659	3,156,921	94,916,666	380,214	5,055,737	266,941	14,553,120	27,646	4,084,568	53,430	11,841,137	1,083,912	114,502,336	5,478	8,126,214	19,877	32,304,517
2026 -27	47,754,652	145,943,783	28,132	1,440,189	3,346,336	105,642,249	391,620	5,467,780	280,288	16,044,815	28,475	4,417,460	55,033	12,806,190	1,138,107	126,238,825	5,752	8,959,150	21,865	37,311,717
2027 -28	49,187,291	157,838,202	28,976	1,557,565	3,547,116	117.579.824	403,369	5,913,404	294,302	17,689,408	29,330	4,777,483	56,684	13,849,894	1,195,013	139,178,304	6.040	9,877,463	24.051	43,095,034
2028 - 29	50,662,910	170,702,015	29,845	1,684,506	3,759,943	130,866,344	415,470	6,395,347	309,018	19,502,573	30,209	5,166,848	58,385	14,978,660	1,254,763	153,444,081	6,342	10,889,903	26,457	49,774,764
2029 - 30	52,182,797	184,614,229	30,741	1,821,794	3,985,540	145,654,241	427,934	6,916,567	324,469	21,501,586	31,116	5,587,946	60,136	16,199,421	1,317,501	169,172,099	6,659	12,006,118	29,102	57,489,852
Total Cost																				
(PKR)	458,483,742	1,330,719,619	270,091	13,131,688	31,093,954	942,830,176	3,759,872	49,855,376	2,630,733	144,108,738	273,387	40,278,526	528,364	116,767,205	10,682,067	1,133,831,588	53,989	80,467,858	196,703	326,995,934
																		ost (PKR)		,986,708
																	. /	in Millions		,179
																Total Cos	st (USD)	in Millions		\$ 26

KHYBER PAKHTUNKHWA - PRIVATE SECTOR CONTRACEPTIVE PROJECTION WITH COSTING (2020-21 TO 2029-30)

					Kilyb											t for the <mark>5 Consu</mark>										
Product s	Con	ndom	P	ОР	С	ос		СР	Сор	per-T-		tiload		nth Inj		onth Inj		lanon		lelle	Fem	nplant	I-Mo	nth Inj	Safe	e Load
5-yr AVG	11,51	11,421	4,	509	115	5,613	188	3,816	26	.094	33	.031	44	,344	50),463	5	42	4	32	2	207	13	,899	2,	.691
l Yr AVG	,	98,761	10	,118	87	.084	19	,461	35	.634	13	,245	27	,323	41	,568		23	6	48		92	9	858	5	,032
5	10,57	70,701	10	,110	02	,001	17	, 101		.051	15	,213	27	,525		,500		25				/2	<i>,</i> ,	050	,	052
rowth 5 o IYr	-9	.7%	124	4.4%	-29	9.0%	1	4%	36	.6%	-59	9.9%	-3	8.4%	-1	7.6%	-9	5.8%	49	9.8%	-5	5.5%	-29	9.1%	86	6.9%
orecast rowth																										
actor	١.	.10	I.	.05	1	.10		.10	1	.10	1	.01		.02	I	.10	1	.05		.10	1	.01		.01	I	.01
i yr vg*gro vth																										
actor	12,66	62,563	4,	735	127	7,175	207	7,698	28	,703	33	,362	45	,231	55	5,510	5	69	4	75	2	209	14	,038	2,	,718
Year	Quantity	Cost(PKR)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti tv	Cost(PK R)	Quanti tv	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti ty	Cost(PK R)	Quanti tv	Cost R)
020 -21	29,568,43	67,431,435	9,616	367,355	296,966	6,995,837	484,996	5,052,989	67.025	2,863,08	60,303	6,980,86	84,210	14,622,53	129.621	10,728,76	1,155	1,342,39	1.110	1,413,82	378	439,330	25,375	2,100,30	4.914	5,710
021 -22	32,525,27	77,883,308	10,097	405,009	326,663	8,080,191	533,495	5,836,202	73,728	3,306,86 I	60,906	7,403,21 I	85,894	15,660,72 9	142,583	12,391,72		1,479,98 7	1,221	1,632,96 5	382	465,910	25,629	2,227,37 7	4,963	6,056
022 -23	35,777,80 2	89,955,221	10,602	446,523	359,329	9,332,621	586,845	6,740,814	81,101	3,819,42 5	61,515	7,851,10 5	87,612	16,772,64 I	156,842	14,312,44 3	1,273	1,631,68 6	1,343	1,886,07 5	386	494,097	25,885	2,362,13 3	5,012	6,422 5
023 -24	39,355,58 2	103,898,28 0	11,132	492,291	395,262	10,779,17 7	645.529	7,785,640	89,211	4,411,43 6	62,131	8,326,09 7	89,364	17,963,49 9	172,526	16,530,87 2	1,337	1,798,93 4	1,478	2,178,41	389	523,990	26,144	2,505,04 2	5,062	6,81
024 -25	43,291,14	120,002,51	11,689	542,751	434,789	12,449,95	710,082	8,992,414	98,132	5,095,20	62,752	8,829,82	91,152	19,238,90	189,778	19,093,15	1,404	1,983,32	1,626	2,516,07	393	555,691	26,406	2,656,59	5,113	7,223
	47,620,25	138,602,90	,			14,379,69	,	10,386,23	,	5,884,96		9,364,03		20,604,86	,	22,052,59		2,186,61	,	2,906,06		, í		2,817,32		7,660
025 -26	4 52,382,27	3 160,086,35	12,273	598,383	478,267	2 16,608,54	781,091	8 11,996,10	107,945	6 6,797,13	63,379	0 9,930,55	92,975	9 22,067,81	208,756	6 25,470,74	1,474	6 2,410,74	1,788	2 3,356,50	397	589,311	26,670	2 2,987,77	5,164	8,12
026 -27	9	3	12,887	659,717	526,094	4	859,200	5	118,740	5	64,013	4	94,834	5	229,632	9	1,548	4	1,967	2	401	624,964	26,936	0	5,216	8
027 -28	57,620,50 7	184,899,73 7	13,531	727,339	578,704	19,182,86 8	945,120	13,855,50 2	130,614	7,850,69 I	64,653	10,531,3 52	96,731	23,634,63 0	252,595	29,418,71 5	1,625	2,657,84 5	2,164	3,876,75 9	405	662,774	27,206	3,168,53 0	5,268	8,61
028 -29	63,382,55	213,559,19	14,208	801,891	636,574	22,156,21	1,039,6 32	16,003,10	143,675	9,067,54	65,300	11,168,4 99	98,665	25,312,68	277,854	33,978,61	1,706	2,930,27	2,380	4,477,65	409	702,872	27,478	3,360,22	5,321	9,136
	69,720,81	246,660,87	,	,		25,590,42	1,143,5	4 18,483,58		o 10,473,0		,844,	100,63	27,109,89		39,245,30	,	3,230,62		5,171,69		,		3,563,51		9,68
29 - 30 otal Cost	4 471,244,6	2 1,402,979,	14,918	884,085 5,925,34	700,231 4,732,8	6 145,555,5	95 7,729,5	6 105,132,5	158,043 1,068,2	18 59,569,3	65,953 630,90	93 92,229,7	9 922,07	0 202,988,1	305,640 2,065,8	l 223,222,9	1,792	7 21,652,4	2,618	4 29,416,0	413	745,396 5,804,33	27,752 265,48	9 27,748,8	5,374	75,4
KR)	41	820	2	5	80	18	84	96	13	72	7	34	5	98	2,003,0	41	14,527	30	17,695	23	3,955	5	Í	25	51,407	5
																							Fotal Co	· /	2,397,	<u> </u>
																						otal Cost otal Cost (<u>\</u>			,398 4.99

BALOCHISTAN - PUBLIC SECTOR CONTRACEPTIVE PROJECTION WITH COSTING (2020-21 TO 2029-30)

				Balochi	stan Pu	blic Sect	o <mark>r* C</mark> or	ntracepti	ives Fo	recast w	ith Cos	t for the	e Period	1 2020-2	I to 202	29-30				
				Rat	ionale f	or Forec	ast / Pro	ojection	s (base	d on July	2016 -	June 20	19 Cor	sumptio	on trend	d)				
Products	Con	dom	Р	OP	C	ос	E	СР	Coppe	r-T-380A	Mul	tiload	2-Mo	nth Inj	3-Mo	onth Inj	Imp	olanon	Ja	delle
I-yr AVG	20,25	4,187		,932	1,06	5,080	166	5,098	98	,081	12	,077	23	,341	39	8,255	2	,013	4	,805
3-month	,	,			,	,		,		,		,		,		,		,		,
AVG	11,72	2,544	5,	,424	834	1,016	6,	912	68	,862	2	290	9	34	29	6,993	1	,392	3	,597
% growth																				
lyrto 3-																				
month	-42	.1%	-54	4.5%	-2	.7%	-95	5.8%	-2	9.8%	-9	7.6%	-9	6.0%	-2	5.4%	-3	0.9%	-2	25.1%
forecast																				
growth																				
factor	1.0	03	1	.03	L	.06	1	.03	1	.05	1	.03		.03	I	.05		.05		1.10
l-yr																				
avg*growth																				
factor	20,86	1,813	12	2,290	1,12	8,985	17	,081	102	2,985	12	,440	24	,041	41	8,168	2	,113	5	,286
Year	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)	Quantity	Cost(PKR)
2020 -21	24,866,167	56,707,822	14,649	559,599	1,466,732	34,552,794	203,919	2,124,557	130,043	5,554,943	14,827	1,716,445	28,656	4,975,965	528,036	43,705,678	2,669	3,101,785	7,674	9,771,694
2021 -22	25,612,152	61,329,510	15,088	605,206	1,554,736	38,457,259	210,037	2,297,708	136,545	6,124,325	15,272	1,856,336	29,516	5,381,506	554,438	48,185,510	2,802	3,419,718	8,441	11,286,306
2022 -23	26,380,517	66,327,865	15,541	654,531	1,648,020	42,802,929	216,338	2,484,972	143,372	6,752,068	15,730	2,007,627	30,401	5,820,099	582,160	53,124,525	2,942	3,770,240	9,285	13,035,684
2023 -24	27,171,932	71,733,586	16,007	707,875	1,746,902	47,639,660	222,828	2,687,497	150,540	7,444,155	16,202	2,171,249	31,313	6,294,437	611,268	58,569,789	3,089	4,156,689	10,214	15,056,215
2024 -25	27,987,090	77,579,873	16,487	765,567	1,851,716	53,022,942	229,513	2,906,528	158,067	8,207,181	16,688	2,348,205	32,253	6,807,433	641,832	64,573,192	3,244	4,582,750	11,235	17,389,928
2025 - 26	28,826,703	83,902,633	16,982	827,960	1,962,819	59,014,535	236,398	3,143,410	165,971	9,048,417	17,189	2,539,584	33,220	7,362,239	673,923	71,191,945	3,406	5,052,482	12,359	20,085,367
2026 - 27	29,691,504	90,740,697	17,491	895,439	2,080,588	65,683,177	243,490	3,399,598	174,269	9,975,880	17,705	2,746,560	34,217	7,962,262	707,619	78,489,119	3,576	5,570,361	13,595	23,198,599
2027 -28	30,582,249	98,136,064	18,016	968,418	2,205,423	73,105,376	250,795	3,676,665	182,983	10,998,408	18,236	2,970,405	35,243	8,611,186	743,000	86,534,254	3,755	6,141,323	14,954	26,794,381
2028 - 29	31,499,716	106,134,153	18,556	1,047,344	2,337,748	81,366,283	258,319	3,976,313	192,132	12,125,745	18,783	3,212,493	36,301	9,312,997	780,150	95,404,015	3,943	6,770,809	16,449	30,947,510
2029 - 30	32,444,708	114,784,087	19,113	1,132,702	2,478,013	90,560,673	266,068	4,300,383	201,739	13,368,633	19,346	3,474,311	37,390	10,072,007	819,158	105,182,926	4,140	7,464,816	18,094	35,744,375
Total Cost																				
(PKR)	285,062,737	827,376,288	167,929	8,164,641	19,332,698	586,205,629	2,337,704	30,997,631	1,635,661	89,599,756	169,978	25,043,215	328,511	72,600,130	6,641,586	704,960,953	33,567	50,030,973	122,300	203,310,058
																		Cost (PKR)		,289,273
																Total Co	ost (PKR)	in Millions	2	,598
																Total Co	st (USD)	in Millions		\$16

BALOCHISTAN - PRIVATE SECTOR CONTRACEPTIVE PROJECTION WITH COSTING (2020-21 TO 2029-30)

						Baloch										the Pe				7-30						
Product s	Con	dom	Р	ОР	С	ос		CP	Сор	ecast / per-T- 30A		tiload		on 2012 nth Inj		6 Consu		on trend	Ĺ	delle	Fem	nplant	I-Mo	nth Inj	Safe	Load
5-yr AVG	.5	1 421	4	509		5.613	1.99	3.816	26	,094	33	.031	44	.344	50	.463		542		132		207	13	.899	2	691
l Yr	11,51	1,721	-т,	507		,015	100	5,010	20	,074	55	,031		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	50	,705		772		132		207	13	,077	Ζ,	571
AVG	10,39	8,761	10	,118	82	,084	19	1,461	35	,634	13	,245	27	,323	41	,568		23	é	548		92	9,	858	5,	032
% growth 5																										
to I Yr	-9.	7%	12	4.4%	-29	9.0%	I	.4%	36	5.6%	-5	9.9%	-3	8.4%	-1	7.6%	-9	5.8%	49	9.8%	-5	5.5%	-29	9.1%	86	5. 9 %
forecast																										
growth factor	١.	10	1	.05	1	.10	1	.10	1	.10		.01		.02	1	.10		.05		.10		.01	1	.01	I	.01
5 yr																										
avg*grow th factor	12.66	2.563	4	735	127	7.175	207	7.698	28	.703	33	.362	45	.231	55	.510	5	569	4	175		209	14	.038	2	718
Year	Quantity	Cost(PK	Quanti	Cost(PK	Quanti	Cost(PK R)	Quantit)	Quanti	Cost(PK R)	Quanti		Quanti	Cost(PK R)	Quantit	Cost(PK	Quanti	Cost(PK R)	Quanti	Cost(PK R)	Quanti	Cost(PK	Quanti	Cost(PK R)	Quanti	Cost(P
	18,384,20	41,925,56	ty	к)	ty	4,349,66	y	3,141,70	ty	1,780,12	ty	4,340,36	ty	,	y	K)	ty	Í	ty	/	ty	K)	ty	1,305,86	ty	3,550,7
2020 -21	20,222,62	4 48,424,02	5,979	228,404	184,639	9 5,023,86	301,547	3,628,66	41,673	2,056,04	37,494	4,602,95	52,358	9,091,573	80,592	6,670,622	718	834,634	690	879,046 1,015,29	235	273,154	15,777	9 1,384,87	3,055	3,765,5
2021 -22	3 22,244,88	7 55,929,75	6,278	251,815	203,103	7 5,802,56	331,701	5 4,191,10	45,840	4 2,374,73	37,869	4 4,881,43	53,405	9,737,074 10,428,40	88,651	7,704,568	754	920,184 1,014,50	759	8 1,172,66	237	289,680	15,935	4	3,086	7 3,993,3
2022 -23	5 24,469,37	l 64,598,86	6,592	277,626	223,413	7 6,701,96	364,871	8 4,840,73	50,425	I 2,742,81	38,247	2 5,176,75	54,473	7	97,516	8,898,776 10,278,08	792	3	835	9 1,354,43	240	307,205	16,094	9 1,557,51	3,116	3 4,234,9
2023 -24	3	2	6,921	306,083	245,755	4	401,359	0	55,467	5	38,630	9	55,562	4	107,268	7	831	9	919	3	242	325,791	16,255	3	3,148	2
2024 -25	26,916,31 I	74,611,68 6	7,267	337,456	270,330	7,740,76 9	441,494	5,591,04 3	61,014	3,167,95 I	39,016	5,489,95 3	56,674	11,961,81 0	117,995	11,871,19 0	873	1,233,13 4	1,011	1,564,37 0	245	345,502	16,418	1,651,74 2	3,179	4,491,1 8
2025 -26	29,607,94 2	86,176,49 7	7,631	372,045	297,363	8,940,58 8	485,644	6,457,65 4	67,115	3,658,98 3	39,406	5,822,09 5	57,807	12,811,09 9	129,794	13,711,22	917	1,359,53 0	1,112	1,806,84 7	247	366,405	16,582	1,751,67 3	3,211	4,762,9
2026 -27	32,568,73	99,533,85 4	8,012	410,180	327,100	10,326,3 79	534,208	7,458,59	73,827	4,226,12	39,800	6,174,33 2	58,963	13,720,68	142,774	15,836,46	962	1,498,88 2	1,223	2,086,90	249	388,572	16,748	1,857,64 9	3,243	5,051,0
2027 -28	35,825,61	114,961,6 01	8.413	452,223	359,810	11,926,9	587,629	8,614,67	81.209	4,881,17	40,198	6,547,87	60,142	14,694,85	157,051	18,291,11	1.010	1,652,51 8	1.345	2,410,37	252	412,081	16,915	1,970,03 7	3,275	5,356,6
	39,408,17	132,780,6			, , , , , , , , , , , , , , , , , , ,	13,775,6	, í	9,949,94		5,637,75	,	6,944,02	í í	15,738,19	,	21,126,23		1,821,90		2,783,98	-	, í	,	2,089,22	,	5,680,7
2028 -29	0 43,348,98	50 153,361,6	8,834	498,576	395,790	48 15,910,8	646,392	7	89,330	7 6,511,61	40,600	6 7,364,13	61,345	0	172,756	9 24,400,80	1,061	2,008,64	1,480	8 3,215,50	254	437,011	17,084	4 2,215,62	3,308	7 6,024,4
2029 - 30 Fotal Cost	8 292,996,8	50 872,304,1	9,275	549,680 3,684,08	435,370 2,942,6	74 90,499,2	711,031 4,805,8	88 65,366,2	98,263 664,16	0 37,037,3	41,006 392,26	9 57,343,9	62,572 573,30	2 126,208,1	190,032 1,284,4	6 138,789,0	1,114	6 13,462,4	1,628	6 18,289,4	257	463,451 3,608,85	17,255	2	3,341	1 46,911
PKR)	39	42	75,202	9	73	93	77	99	3	18	7	32	I	21	30	93	9,032	21	11,002	43	2,459		3	60	31,962	82
																						otal Cost	Total Co			757,44 491
																						otal Cost	<u> </u>		,	471 9.32

The highly diverse and disorganized structure of the private and commercial market operators poses a serious challenge in obtaining accurate data for future projections. The highlighted portion of the table below pertains to the commercial sector's contribution in percentage terms. However, in the wake of rapid urbanization in the last five years, these figures are likely to change and the commercial sector's share in contraceptives market may be increased. The table below has been copied from PDHS 2017-18 and the data pertaining to commercial enterprises is highlighted in yellow.

Table 7.8 Source of modern contraception methods

Percent distribution of users of modern contraceptive methods age 15-49 by most recent source of method, according to method, Pakistan DHS 2017-18

Public sector 56.8 64.3 61.7 85.8 37.5 19.5 43.5 Government hospital 54.2 40.7 29.0 56.5 3.7 1.6 28.0 Rural health centre 0.0 1.5 2.7 2.8 2.4 0.6 0.8 Family health clinic/RHSC 2.6 4.0 1.7 0.9 2.1 0.6 1.8 Family welfare centre or FWW 0.0 3.2 3.7 12.5 0.7 0.5 1.1 Mother-child health centre 0.0 4.4 0.5 0.0 0.7 0.0 0.5 Basic health unit 0.0 5.1 3.0 2.3 0.8 0.1 0.8 Lady health visitor 0.0 1.4 2.3 0.0 1.7 0.3 0.6 Community midwife 0.0 1.3 0.8 0.0 7.4 0.0 0.2 0.4 Private Medical sector 41.9 30.8 34.0 14.2 47.6	Source	Female sterilisation	IUD	Iniectables	Implants	Pill	Male condom	Total
Government hospital 54.2 40.7 29.0 56.5 3.7 1.6 28.0 Rural health centre 0.0 1.5 2.7 2.8 2.4 0.6 0.8 Family health clinic/RHSC 2.6 4.0 1.7 0.9 2.1 0.6 1.8 Family welfare centre or FWW 0.0 3.2 3.7 12.5 0.7 0.5 1.1 Mother-child health centre 0.0 4.4 0.5 0.0 0.7 0.0 0.5 Basic health unit 0.0 5.1 3.0 2.3 0.8 0.1 0.8 Lady health worker 0.0 1.4 2.3 0.0 1.7 0.3 0.6 Community midwife 0.0 1.3 0.8 0.0 7.4 0.0 0.5 0.4 Private medical sector 41.9 30.8 34.0 14.2 47.6 49.0 42.5 Private MGO hospital/Clinic 29.4 23.5 10.8 11.4 3.4								
Rural health centre 0.0 1.5 2.7 2.8 2.4 0.6 0.8 Family health clinic/RHSC 2.6 4.0 1.7 0.9 2.1 0.6 1.8 Family welfare centre or FWW 0.0 3.2 3.7 12.5 0.7 0.5 1.1 Mother-child health centre 0.0 4.4 0.5 0.0 0.7 0.0 0.5 Basic health unit 0.0 5.1 3.0 2.3 0.8 0.1 0.8 Lady health worker 0.0 2.0 18.0 3.3 25.5 15.3 9.3 Lady health worker 0.0 1.4 2.3 0.0 1.7 0.3 0.6 Community midwife 0.0 1.3 0.8 0.0 7.4 0.0 0.5 0.4 Private medical sector 41.9 30.8 34.0 14.2 47.6 49.0 42.5 Private MGO hospital/clinic 29.4 23.5 10.8 11.4 3.4								
Family health clinic/RHSC 2.6 4.0 1.7 0.9 2.1 0.6 1.8 Family welfare centre or FWW 0.0 3.2 3.7 12.5 0.7 0.5 1.1 Mother-child health centre 0.0 4.4 0.5 0.0 0.7 0.0 0.5 Basic health unit 0.0 5.1 3.0 2.3 0.8 0.1 0.8 Lady health worker 0.0 2.0 18.0 3.3 25.5 15.3 9.3 Lady health visitor 0.0 1.4 2.3 0.0 1.7 0.3 0.6 Community midwife 0.0 1.3 0.8 0.0 0.0 0.2 0.4 0.5 0.4 Private medical sector 41.9 30.8 34.0 14.2 47.6 49.0 42.5 Private/NGO hospital/clinic 29.4 23.5 10.8 11.4 3.4 1.7 14.8 Pharmacy/medical store 0.0 0.0 6.0 0.0 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
Family welfare centre or FWW 0.0 3.2 3.7 12.5 0.7 0.5 1.1 Mother-child health centre 0.0 4.4 0.5 0.0 0.7 0.0 0.5 Basic health unit 0.0 5.1 3.0 2.3 0.8 0.1 0.8 Lady health worker 0.0 2.0 18.0 3.3 25.5 15.3 9.3 Lady health visitor 0.0 1.4 2.3 0.0 1.7 0.3 0.6 Community midwife 0.0 1.3 0.8 0.0 0.0 0.2 Other public 0.0 0.8 0.0 7.4 0.0 0.5 0.4 Private medical sector 41.9 30.8 34.0 14.2 47.6 49.0 42.5 Private //GO hospital/clinic 29.4 23.5 10.8 11.4 3.4 1.7 14.8 Pharmacy/medical store 0.0 0.0 0.0 0.5 0.4 0.1 0.8 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>								
Mother-child health centre 0.0 4.4 0.5 0.0 0.7 0.0 0.5 Basic health unit 0.0 5.1 3.0 2.3 0.8 0.1 0.8 Lady health worker 0.0 2.0 18.0 3.3 25.5 15.3 9.3 Lady health visitor 0.0 1.4 2.3 0.0 1.7 0.3 0.6 Community midwife 0.0 1.3 0.8 0.0 0.0 0.22 Other public 0.0 0.8 0.0 7.4 0.0 0.5 0.4 Private medical sector 41.9 30.8 34.0 14.2 47.6 49.0 42.5 Private Medical sector 12.4 7.0 11.3 2.8 5.1 0.2 6.7 Dispenser/compounder 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.0 Other private 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.0	,							
Basic health unit 0.0 5.1 3.0 2.3 0.8 0.1 0.8 Lady health worker 0.0 2.0 18.0 3.3 25.5 15.3 9.3 Lady health worker 0.0 1.4 2.3 0.0 1.7 0.3 0.6 Community midwife 0.0 1.3 0.8 0.0 0.0 0.2 Other public 0.0 0.8 0.0 7.4 0.0 0.5 0.4 Private medical sector 41.9 30.8 34.0 14.2 47.6 49.0 42.5 Private/NGO hospital/clinic 29.4 23.5 10.8 11.4 3.4 1.7 14.8 Pharmacy/medical store 0.0 0.2 5.9 0.0 35.8 47.0 20.1 Private doctor 12.4 7.0 11.3 2.8 5.1 0.2 6.7 Dispenser/compounder 0.0 0.0 0.0 0.0 13.5 30.5 12.8								
Lady health worker 0.0 2.0 18.0 3.3 25.5 15.3 9.3 Lady health visitor 0.0 1.4 2.3 0.0 1.7 0.3 0.6 Community midwife 0.0 1.3 0.8 0.0 0.0 0.0 0.2 Other public 0.0 0.8 0.0 7.4 0.0 0.5 0.4 Private medical sector 41.9 30.8 34.0 14.2 47.6 49.0 42.5 Private/NGO hospital/clinic 29.4 23.5 10.8 11.4 3.4 1.7 14.8 Pharmacy/medical store 0.0 0.2 5.9 0.0 35.8 47.0 20.1 Private doctor 12.4 7.0 11.3 2.8 5.1 0.2 6.1 0.8 Other private 0.0 0.0 0.0 0.0 0.1 0.8 0.0 0.1 Other private 0.0 0.0 0.0 0.0 0.1 1.5 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
Lady health visitor 0.0 1.4 2.3 0.0 1.7 0.3 0.6 Community midwife 0.0 1.3 0.8 0.0 0.0 0.0 0.2 Other public 0.0 0.8 0.0 7.4 0.0 0.5 0.4 Private medical sector 41.9 30.8 34.0 14.2 47.6 49.0 42.5 Private/NGO hospital/clinic 29.4 23.5 10.8 11.4 3.4 1.7 14.8 Pharmacy/medical store 0.0 0.2 5.9 0.0 35.8 47.0 20.1 Private doctor 12.4 7.0 11.3 2.8 5.1 0.2 6.7 Dispenser/compounder 0.0 0.0 6.0 0.0 2.4 0.1 0.8 Other private 0.0 0.0 0.0 0.0 0.8 0.0 0.1 Other private 0.0 0.0 0.0 0.6 0.0 9.7 27.8 10.9<								
Community midwife 0.0 1.3 0.8 0.0 0.0 0.0 0.2 Other public 0.0 0.8 0.0 7.4 0.0 0.5 0.4 Private medical sector 41.9 30.8 34.0 14.2 47.6 49.0 42.5 Private/NGO hospital/clinic 29.4 23.5 10.8 11.4 3.4 1.7 14.8 Pharmacy/medical store 0.0 0.2 5.9 0.0 35.8 47.0 20.1 Private doctor 12.4 7.0 11.3 2.8 5.1 0.2 6.7 Dispenser/compounder 0.0 0.0 0.0 0.0 0.0 0.1 0.8 Other private 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.0 0.1 Other private 0.0 0.0 0.0 0.8 0.0 0.1 0.8 Other private 0.0 0.0 0.0 0.7 2.8 10.9								
Other public 0.0 0.8 0.0 7.4 0.0 0.5 0.4 Private medical sector 41.9 30.8 34.0 14.2 47.6 49.0 42.5 Private/NGO hospital/clinic 29.4 23.5 10.8 11.4 3.4 1.7 14.8 Pharmacy/medical store 0.0 0.2 5.9 0.0 35.8 47.0 20.1 Private doctor 12.4 7.0 11.3 2.8 5.1 0.2 6.7 Dispenser/compounder 0.0 0.0 0.0 0.0 0.8 0.0 0.1 Other private 0.0 0.0 0.0 0.0 0.8 0.0 0.1 Other private 0.0 0.0 0.0 0.0 0.8 0.0 0.1 Other source 0.0 0.0 0.6 0.0 9.7 27.8 10.9 Shop 0.0 0.0 0.0 0.0 0.7 0.0 0.0 Lit a								
Private medical sector 41.9 30.8 34.0 14.2 47.6 49.0 42.5 Private/NGO hospital/clinic 29.4 23.5 10.8 11.4 3.4 1.7 14.8 Pharmacy/medical store 0.0 0.2 5.9 0.0 35.8 47.0 20.1 Private doctor 12.4 7.0 11.3 2.8 5.1 0.2 6.7 Dispenser/compounder 0.0 0.0 6.0 0.0 2.4 0.1 0.8 Other private 0.0 0.0 0.0 0.0 0.0 13.5 30.5 12.8 Shop 0.0 0.0 0.6 0.0 9.7 27.8 10.9 Friend/relative 0.0 0.0 0.0 0.7 0.0 0.0 0.5 Gother 0.0 0.0 0.0 0.0 0.7 0.0 0.1 Other private 0.0 0.0 0.0 0.6 0.0 0.7 12.8								
Private/NGO hospital/clinic 29.4 23.5 10.8 11.4 3.4 1.7 14.8 Pharmacy/medical store 0.0 0.2 5.9 0.0 35.8 47.0 20.1 Private doctor 12.4 7.0 11.3 2.8 5.1 0.2 6.7 Dispenser/compounder 0.0 0.0 6.0 0.0 2.4 0.1 0.8 Other private 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.1 Other source 0.0 4.9 3.4 0.0 13.5 30.5 12.8 Shop 0.0 0.0 0.0 0.0 9.7 27.8 10.9 Friend/relative 0.0 0.0 0.0 0.7 0.0 0.0 Dai, traditional birth attendant 0.0 4.9 0.9 0.0 0.6 0.0 0.5 Other 0.0 0.0 0.0 0.0 0.0 0.0 0.5 Othe								
Pharmacy/medical store 0.0 0.2 5.9 0.0 35.8 47.0 20.1 Private doctor 12.4 7.0 11.3 2.8 5.1 0.2 6.7 Dispenser/compounder 0.0 0.0 6.0 0.0 2.4 0.1 0.8 Other private 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.1 Other source 0.0 4.9 3.4 0.0 13.5 30.5 12.8 Shop 0.0 0.0 0.6 0.0 9.7 27.8 10.9 Friend/relative 0.0 0.0 0.0 0.0 0.7 0.0 0.0 Dai, traditional birth attendant 0.0 4.9 0.9 0.0 0.6 0.0 0.5 Other 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0.5 Other source 0.0 0.0 0.0 0.0 0.0 0.5 0.0 0								
Private doctor 12.4 7.0 11.3 2.8 5.1 0.2 6.7 Dispenser/compounder 0.0 0.0 6.0 0.0 2.4 0.1 0.8 Other private 0.0 0.0 0.0 0.0 0.0 0.8 0.0 0.1 Other source 0.0 4.9 3.4 0.0 13.5 30.5 12.8 Shop 0.0 0.0 0.6 0.0 9.7 27.8 10.9 Friend/relative 0.0 0.0 0.0 0.0 0.7 20.0 10.9 Hakim 0.0 0.0 0.0 0.0 0.7 0.0 0.0 Dai, traditional birth attendant 0.0 4.9 0.9 0.0 0.6 0.0 0.5 Other 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Dai, traditional birth attendant 0.0 0.0 0.0 0.0 0.0 0.1 0.7 <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td<>								
Dispenser/compounder 0.0 0.0 6.0 0.0 2.4 0.1 0.8 Other private 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.8 0.0 0.1 0.8 0.0 0.1 0.8 0.0 0.1 0.8 0.0 0.1 0.8 0.0 0.1 0.1 0.8 0.0 0.1								
Other private 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 Other source 0.0 4.9 3.4 0.0 13.5 30.5 12.8 Shop 0.0 0.0 0.6 0.0 9.7 27.8 10.9 Friend/relative 0.0 0.0 0.0 1.9 0.0 2.6 2.7 1.4 Hakim 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 Dai, traditional birth attendant 0.0 4.9 0.9 0.0 0.1 0.7 0.3 Other 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Dai, traditional birth attendant 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Don't know 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.7 Missing 1.1 0.0 0.9 0.0 1.3 <th< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th<>								
Other source 0.0 4.9 3.4 0.0 13.5 30.5 12.8 Shop 0.0 0.0 0.0 0.6 0.0 9.7 27.8 10.9 Friend/relative 0.0 0.0 0.0 1.9 0.0 2.6 2.7 1.4 Hakim 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 Dai, traditional birth attendant 0.0 4.9 0.9 0.0 0.6 0.0 0.5 Other 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Don't know 0.2 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Missing 1.1 0.0 0.9 0.0 1.3 0.3 0.7								
Shop 0.0 0.0 0.6 0.0 9.7 27.8 10.9 Friend/relative 0.0 0.0 1.9 0.0 2.6 2.7 1.4 Hakim 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 Dai, traditional birth attendant 0.0 4.9 0.9 0.0 0.6 0.0 0.5 Other 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Don't know 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Missing 1.1 0.0 0.9 0.0 1.3 0.3 0.7	Other private	0.0	0.0	0.0	0.0	0.8	0.0	0.1
Shop 0.0 0.0 0.6 0.0 9.7 27.8 10.9 Friend/relative 0.0 0.0 1.9 0.0 2.6 2.7 1.4 Hakim 0.0 0.0 0.0 0.0 0.0 0.7 0.0 0.0 Dai, traditional birth attendant 0.0 4.9 0.9 0.0 0.6 0.0 0.5 Other 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Don't know 0.2 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Missing 1.1 0.0 0.9 0.0 1.3 0.3 0.7	Other source	0.0	49	34	0.0	13.5	30.5	12.8
Friend/relative Hakim 0.0 0.0 1.9 0.0 2.6 2.7 1.4 Dai, traditional birth attendant 0.0<								
Hakim 0.0 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
Dai, traditional birth attendant 0.0 4.9 0.9 0.0 0.6 0.0 0.5 Other 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Don't know 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Missing 1.1 0.0 0.9 0.0 1.3 0.3 0.7								
Other 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Don't know 0.2 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.7 0.3 Missing 1.1 0.0 0.9 0.0 1.3 0.3 0.7	Dai, traditional birth attendant							
Don't know 0.2 0.0 0.0 0.0 0.0 0.1 Missing 1.1 0.0 0.9 0.0 1.3 0.3 0.7			_			-		_
Missing (1.1 0.0 0.9 0.0 1.3 0.3 0.7								
Total 100.0 100.0 100.0 100.0 100.0 100.0 99.8	Missing	1.1	0.0	0.9	0.0	1.3	0.3	0.7
	Total	100.0	100.0	100.0	100.0	100.0	100.0	99.8
Number of women 1,087 254 296 53 197 1,092 2,989	Number of women	1,087	254	296	53	197	1,092	2,989

Note: Table excludes Azad Jammu and Kashmir and Gilgit Baltistan. Total includes six women whose husbands are sterilised, four women using emergency contraception, and one woman using the standard days method (SDM); it excludes women using the lactational amenorrhoea method (LAM).

INVESTMENT GROWTH POTENTIAL

On the basis of the above tabular analysis for public, private, and commercial sectors, it is evident that there is huge potential for venture capitalists, pharmaceutical industry investors, and existing suppliers to benefit from the high return on investment (ROI) besides affording opportunity to attract foreign investment. The projections conducted above offer a promising ROI to the new entrants as well. The table below summarizes projected revenues till 2030.

Projected market till 2030 – Entire Country

Description	PKR in million	USD in Million
Public Sector	28,713	\$179
Private Sector/NGOs	16,764	\$103
Commercial Sector	7,544	\$47
Total	52,731	\$330

Projected market till 2030 – Punjab province

Description	PKR in million	USD in Million
Public Sector	14,789.4	\$92.4
Private Sector/NGOs	8,485.3	\$53
Commercial Sector	3,886	\$24.3
Total	27,161	\$170

Projected market till 2030 – Sindh province

Description	PKR in million	USD in Million
Public Sector	7,146	\$44.7
Private Sector/NGOs	4,100	\$25.6
Commercial Sector	1,878	\$11.7
Total	13,124	\$82

Projected market till 2030 - Khyber Pakhtunkhwa province

Description	PKR in million	USD in Million
Public Sector	4,179	\$26
Private Sector/NGOs	2,398	\$15
Commercial Sector	1,098	\$7
Total	7,675	\$48

Projected market till 2030 – Balochistan province

Description	PKR in million	USD in Million
Public Sector	2,598	\$16.2
Private Sector/NGOs	1,491	\$9.3
Commercial Sector	683	\$4.3
Total	4,772	\$30

It would be a prudent economic decision for the investors to tap into a largely expanding consumer market whose family planning needs must be domestically met through local production. It is a promising opportunity for the national pharmaceutical companies to step forward mobilize their resources.

The tables below are titled accordingly. The first set of tables contains national level tabular analysis of the internationally produced products and their projection as well as financial impact till 2030. The first table contains the commodities that are currently being procured from international market which includes condoms, intrauterine devices and implants. A guick scan of the tabular analysis reveals that condoms alone are the big-ticket items and a huge amount of financial allocation is required in the years to come to fulfil the requirements of the population using barrier method. Approximately PKR 24,774 million would be required to provide condoms to the users. Though the share of intrauterine devices and implants in the table below is not substantial, however, the current shift from short acting method to long acting methods may significantly impact the cost estimation which has been currently calculated at approximately PKR 6,101 million. For Punjab approximately PKR 12.761 million would be required to provide condoms to the users and PKR 3,143 million would be spent on providing intrauterine devices and implants. Similarly, approximately PKR 6,166 million would be required to provide condoms to the users in Sindh and PKR 1,518 million would be spent on providing intrauterine devices and implants. For Khyber Pakhtunkhwa approximately PKR 3,606 million would be required to provide condoms to the users besides spending PKR 888 million on intrauterine devices and implants. Balochistan's share of condoms would be around PKR 2,242 million and for intrauterine devices and implants PKR 552 million would be needed.

Given the foregoing scenario, it is evident that a sizeable amount of business opportunity exists for the potential investors, pharmaceutical industry and other entrepreneurs. It could also accrue financial benefits to the provincial and regional governments through local manufacturing of these commodities. The local manufacturing will help in forestalling the incidence of stock-out and would ensure availability of supplies at the last mile besides contributing the national exchequer.

Within the tables below, there are commodities that are locally produced in Pakistan and these tables represent the commodities requirement till 2030. The estimated cost of these products for the entire country is approximately PKR 19,337 million.

		INATIO	INAL KI	EQUIRE	ITICINI V		031 4		030		
		Internation	nally Procur	ed Contrace	otives Nationa	l Requirem	ent with Co	st 2020 to 203	10 [1]		
			Public Sector		F	Private Sector		Commercial Sector			
S.No	Product	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions	
1	Condom	3,150,115,723	9,143	57	3,237,792,355	9,639	60	2,037,742,677	5,992	37	
2	POP	1,855,722	90	1	831,027	41	0.3				
3	2 Month Inj.	3,630,244	802 5 6,335,326 1,395 9								
4	1 Month Inj.	0	0	0	1,824,044	191	1				
5	Cu-T	18,075,049	990	6	7,339,398	409	3	1,499,452	83	1	
6	Multiload	1,878,364	277	2	4,334,786	634	4				
7	Safeload	0	0	0	353,205	518	3				
8	Femplant	0	0	0	27,172	40	0.2				
9	Implanon	370,940	553	3	99,813	149	1				
10	Jadelle	1,351,492	2,247	14	121,578	202	1				
	Total		14,102	88		13,218	83	2,039,242,129	6,074	38	
	imated produ Pakistan mar					PKR 33,394m	illion (\$209 m	illion)			

INTERNATIONALLY & LOCALLY MANUFACTURED CONTRACEPTIVE NATIONAL REQUIREMENT WITH COST -- 2020 TO 2030

[1] New method e.g., SayanaPress or change in method mix or production needs for other regional countries and markets will require adjustment

	Locally Manufactured Contraceptives National Requirement with Cost 2020 to 2030[2]												
			Public Sector			Private Sector		Commercial Sector					
S.No	Product	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions			
1	COC	213,638,006	6,478	40	32,518,317	1,000	6	33,231,104	1010	6			
2	ECP	25,833,048	343	2	53,107,844	722	5	10,657,021	144	1			
3	DMPA	73,393,545	7,790	49	14,193,731	1,534	10	2,977,967	317	2			
	Total		14,611	91		3,256	20	46,866,091	1,470	9			
	ed total Paki isting local p	istan market for production			PKR 19,337 million (\$121 million)								

[2] Change in method mix, local market trend, and needs of exports will require adjustments

INTERNATIONALLY & LOCALLY MANUFACTURED CONTRACEPTIVE PUNJAB REQUIREMENT WITH COST -- 2020 TO 2030

		Internatio	onally Procur	ed Contra	ceptive Req	uirement wit	h Cost 2	020 to 2030[I]	1	
			Public Sector			Private Sector		Commercial Sector		
S.No	Product	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions
I	Condom	1,622,568,318	4,709	29	1,667,728,984	4,965	31	1,049,604,839	3,086	19
2	POP	955,849	46	0	428,047	21	0			
3	2-Month Inj	1,869,874	413	3	3,263,213	718	4			
4	I-Month Inj			0	939,532	98	I			
5	Cu-T	9,310,131	510	3	3,780,393	211	I	772,341	43	0
6	Multiload	967,512	143	I	2,232,771	326	2			
7	Safeload			0	181,929	267	2			
8	Femplant			0	13,996	21	0			
9	Implanon	191,065	285	2	51,412	77	0			
10	Jadelle	696,129	1,157	7	62,623	104	I			
Total			7,264	45		6,808	43		3,129	20
Estimate	d productior market ald	n value Punjab one			PKR	t 17,201 million (\$107.5 million)		

[1] New method e.g., SayanaPress or change in method mix or production needs for other regional countries and markets will require adjustment

		Locall	y Produced	Contracep	tive Require	ment with C	ost 2020 1	to 2030 [2]		
			Public Sector			Private Sector		Commercial Sector		
S.No	Product	Quantity	Cost PKR	Cost USD	Quantity	Cost PKR	Cost USD	Quantity	Cost PKR	Cost USD
		Quantity	millions	millions	Quantity	millions	millions	Quantity	millions	millions
I	COC	110,041,119	3,337	21	16,749,604	515	3	17,116,748	520	3.2
2	ECP	13,306,142	176	I	27,354,902	372	2	5,489,241	74	0.5
3	DMPA	37,803,703	4,013	25	7,310,937	790	5	1,533,898	163	1.0
	Total			47		1,677	10		757	4.7
	ted Punjab (kisting local	total market production			PKI	R 9,960 million (\$62.3 million)		

[2] Change in method mix, local market trend, and needs of exports will require adjustments

INTERNATIONALLY & LOCALLY MANUFACTURED CONTRACEPTIVE SINDH REQUIREMENT WITH COST -- 2020 TO 2030

	I	nternation	ally Procured	Contrace	ptive Requi	rement wit	th Cost	2020 to 20	30*	
			Public Sector		P	rivate Sector		Com	mercial Sect	or
S.No	Product	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions
I	Condom	784,000,927	2,276	14	805,821,890	2,399	15	507,153,479	1,491	9.3
2	POP	461,852	22	0	206,826	10				
3	2-Month Inj	903,495	200	Ι	1,576,736	347				
4	I-Month Inj			0	453,968	47				
5	Cu-T	4,498,517	246	2	1,826,630	102	I	373,184	21	0.1
6	Multiload	467,487	69	0	1,078,842	158	I			
7	Safeload				87,906	129				
8	Femplant				6,762	10				
9	Implanon	92,320	138	Ι	24,842	37	0			
10	Jadelle	336,359	559	3	30,258	50	0			
	Total		3,510	22		3,290	21		1,512	9.4
Estimat	ed productio market ale	on value Sindh one			PKR 8,	311 million (\$	51.9 million)		

[1] New method e.g., SayanaPress or change in method mix or production needs for other regional countries and markets will require adjustment

		Locally F	Produced Co	ntraceptiv	e Requirem	ent with C	ost 202	0 to 2030*	-		
			Public Sector		Pi	rivate Sector		Commercial Sector			
S.No	Product	Quantity	Cost PKR	Cost USD	Quantity	Cost PKR	Cost USD	Quantity	Cost PKR	Cost USD	
		Quantity	millions	millions	Quantity	millions	millions	Quality	millions	millions	
Ι	COC	53,170,235	1,612	10	8,093,160	249	2	8,270,558	251	1.6	
2	ECP	6,429,330	85	I	13,217,482	180	I	2,652,320	36	0.2	
3	DMPA	18,266,188	1,939	12	3,532,536	382	2	741,157	79	0.5	
	Total		3,636	23		810	5		366	2.3	
		otal market	PKR 4,813 million (\$30.1 million)								
for ex	isting local	production									

[2] Change in method mix, local market trend, and needs of exports will require adjustments

INTERNATIONALLY & LOCALLY MANUFACTURED CONTRACEPTIVE KHYBER PAKHTUNKHWA REQUIREMENT WITH COST -- 2020 TO 2030

	lr	nternational	lly Procure	d Contrac	eptive Requ	uirement w	ith Cost	2020 to 20	30[1]	
		Р	ublic Sector		P	rivate Sector		Com	mercial Sec	tor
S.No	Product	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions
Ι	Condom	458,483,742	1,331	8	471,244,641	1,403	8.77	296,583,354	872	5.45
2	POP	270,091	13	0.08	120,952	6	0.04			
3	2-Month Inj	528,364	117	0.73	922,075	203	1.27			
4	I-Month Inj				265,481	28	0.17			
5	Cu-T	2,630,733	144	I	1,068,213	60	0.37	218,238	12	0.08
6	Multiload	273,387	40	0.3	630,907	92	0.58			
7	Safeload				51,407	75	0.47			
8	Femplant				3,955	6	0.04			
9	Implanon	53,989	80	I	14,527	22	0.14			
10	Jadelle	196,703	327	2	17,695	29	0.18			
	Total		2,052	13		1,924	12		884	5.53
	nated produc er Pakhtunkh				РК	R 4,860 million	n (\$30.4 milli	on)		

[1] New method e.g., SayanaPress or change in method mix or production needs for other regional countries and markets will require adjustment

		Locally Mar	nufactured	Contrace	ptive Requi	rement wit	h Cost 2	020 to 203	0[2]	
		P	ublic Sector		P	rivate Sector		Commercial Sector		
S.No	Product	Quantita	Cost PKR	Cost USD	Quantita	Cost PKR	Cost USD	Quantita	Cost PKR	Cost USD
	Quantity		millions	millions	Quantity	millions	millions	Quantity	millions	millions
1	COC	31,093,954	943	6	4,732,880	146	0.9	4,836,623	147	0.9
2	ECP	3,759,872	50	0	7,729,584	105	0.7	1,551,077	21	0.1
3	DMPA	10,682,067	1,134	7	2,065,827	223	1.4	433,428	46	0.3
	Total		2,127	13		474	3.0		214	1.3
	ted total KP ting local pr	' market for oduction			PK	R 2,814 million	ı (\$17.6 millio	on)		

[2] Change in method mix, local market trend, and needs of exports will require adjustments

INTERNATIONALLY & LOCALLY MANUFACTURED CONTRACEPTIVE BALOCHISTAN REQUIREMENT WITH COST -- 2020 TO 2030

	Int	ternationall	y Procured	Contrace	ptive Requi	rement w	ith Cost	2020 to 20	30[1]	-
		P	ublic Sector		Pr	ivate Sector	r	Corr	nmercial Sec	tor
S.No	Product	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions	Quantity	Cost PKR millions	Cost USD millions
I	Condom	285,062,737	827	5	292,996,839	872	5.45	184,401,005	542	3.39
2	POP	167,929	8	0	75,202	4	0.02			
3	2-Month Inj	328,511	73	0	573,301	126	0.79			
4	I-Month Inj			0	165,063	17	0.11			
5	Cu-T	1,635,661	90	I	664,163	37	0.23	135,690	7	0.05
6	Multiload	169,978	25	0.2	392,267	57	0.36			
7	Safeload			0.0	31,962	47	0.29			
8	Femplant			0.0	2,459	4	0.02			
9	Implanon	33,567	50	0	9,032	13	0.08			
10	Jadelle	122,300	203	I	11,002	18	0.11			
	Total 1,276 8					1,196	7		550	3.44
	Estimated production value Balochistan market alone				PKR	3,022 millio	n (\$18.9mill	ion)		

[1] New method e.g., SayanaPress or change in method mix or production needs for other regional countries and markets will require adjustment

	L	ocally Man	ufactured C	ontracep	tive Requir	ement wit	h Cost 2	2020 to 203	0 [2]		
		P	ublic Sector		Pi	rivate Sector	•	Commercial Sector			
S.No	Product	Quantity	Cost PKR	Cost USD	Quantity	Cost PKR	Cost USD	Quantity	Cost PKR	Cost USD	
	- ,		millions	millions	Quantity	millions	millions	Quantity	millions	millions	
I	COC	19,332,698	586	4	2,942,673	90	0.6	3,007,175	91	0.6	
2	ECP	2,337,704	31	0.2	4,805,877	65	0.4	964,383	13	0.1	
3	DMPA	6,641,586	705	4	1,284,430	139	0.9	269,485	29	0.2	
	Total		1,322	8		295	1.8		133	0.8	
Est	timated total	market		-	PKR	1 750 millio	n (\$10 9 mill	ion)	-		
Baloc	histan for ex	isting local	PKR 1,750 million (\$10.9 million)								

[2] Change in method mix, local market trend, and needs of exports will require adjustments

Whereas the tables below contain analysis of local production of COC, ECP, and DMPA by Zafa and Hensel. In 2014-15, the Government of the Punjab procured locally produced contraceptives (COC, ECP and DMPA) worth PKR 595 million. The following year, KP, Punjab and Sindh procured the products of worth PKR 536 million. During the fiscal year 2016-17, all four provinces sourced the locally produced contraceptives worth PKR 775 million. In addition to the national level analysis, the four tables below contain provincially desegregated costs on yearly basis as per their procurement on the locally produced commodities.

Year	PKR in million	USD in million
2014-15	595	5.67
2015-16	536	5.10
2016-17	775	7.38
Total	I,906	18.15

Punjab's Cost on locally produced products

Year	PKR in million	USD in million
2014-15	595	5.66
2015-16	119	1.12
2016-17	229	2.18

Total	943	8.96
-------	-----	------

Sindh's Cost on locally produced products

Year	PKR in million	USD in million
2015-16	274	2.6
2016-17	347	3.3
Total	621	5.9

Khyber Pakhtunkhwa's Cost on locally produced products

Year	PKR in million	USD in million
2015-16	40	0.38
2016-17	39	0.37

Baluchistan's Cost on locally produced products

Year	PKR in million	USD in million
2016-17	54.49	0.51

The main barriers impeding local production have been a high-dependency on external aid for contraceptives and fragmentary cooperation between local manufacturers, technical and development partners, and national authorities. Therefore, a significant degree of coherence across health, trade, investment and intellectual property areas is essential for Pakistan to reap the maximum benefit of a viable pharmaceutical sector particularly in family planning commodities. This would result in significant saving in public funds and would ensure sustainable and uninterrupted supply of FP commodities.

Restraining the unprecedented population growth, and ultimately harmonizing it to a tolerable level requires multipronged strategies focused on ensuring commodity security of FP goods. Since Pakistan aims to achieve targets of universal access of FP commodities, the provincial governments have ramped up their financial allocations for the procurement of contraceptives. Other concomitant efforts of removing structural barriers to access and strengthening of overall health systems are also underway.

Producing a full range of the family planning commodities to be procured by the provincial governments in Pakistan in the years to come is economically viable and less risky from a market niche perspective. In the wake of the new census figures ringing alarm bells in terms of unprecedented growth, the investment climate for such investment seems highly conducive for local production of contraceptives that are currently being imported from the international market.

WAY FORWARD

- 1. The PPW should arrange meetings with potential local manufacturers and pharmaceutical industries to stir private sector interest, attract investments in local production of contraceptives and devise a roadmap. The roadmap will aim on how the MoNHSR&C / PPW can facilitate and assist the local interested manufacturers in registration, licensing of contraceptive products, rebates on import of machinery and equipment, and waivers on commercial taxes. The GHSC-PSM project will provide technical support to the PPW for arranging the meetings.
- 2. The PPW should coordinate with all provincial governments to partner with them and to solicit their commitments to purchase the contraceptives from the potential local investors. If there is no commitment on the part of the provincial governments to give confirmed

business to the potential investors, the likelihood of investment in local manufacturing of contraceptives would be minimal.

ANNEXURE-I: PPW REQUEST FOR COMMISSIONING STUDY

No.12-2/2017-P&S GOVERNMENT OF PAKISTAN M/O NATIONAL HEALTH SERVICES, REGULATIONS & COORDINATION (Population Programme Wing) 10th Floor, Shaheed-e-Millat Secretariat

Islamabad, the 26th April 2017

Subject:- REQUEST FOR COMMISSIONING OF FEASIBILITY STUDY ON THE MANUFACTURING OF CONTRACEPTIVES IN PAKISTAN

Dear Ms. Monica Villanueva,

Please recall our meeting of 16th March 2017. This meeting was followed up by another meeting with the Technical Team of USAID Global Health Supply Chain Programme on 22nd March 2017. As an outcome of the aforesaid meetings, the following are identified components / dimensions of the feasibility study:-

S.No.	Area of Technical Assistance	Responsibility
i.	Desk review outlining existing method mix, including quantities ordered and consumed over the past 10 years.	
ii.	The projection of the demand of the method mix till 2030 while keeping in view: a. Pakistan commitments in FP 2020; b. Vision 20205 and SDGs;	Global Health Supply Chain Programme (GHSCP).
iii.	Provincial preparedness for procurement in terms of their choice, method-mix requirements and funding allocation for contraceptive procurement as reflected in their CIPs.	
iv.	Writing a letter of intent to private sector / pharmaceutical companies.	Population Programme Wing (PPW)
V.	Holding a briefing session with short-listed / interested organizations and invite their technical proposals to determine potential investments to gain access to internal and external markets and commercial advantage.	Population Programme Wing supported by Global Health Supply by Global Health Supply Chain Programme.
vi.	Evaluation of Technical proposal and award of contract. Coordinate and sign MoUs with the Provincial Government(s) for obtaining of commitment to purchase contraceptives from potential investors.	Committee chaired by: * Additional Secretary
vii.	Facilitate interested firms on the following: a. Facilitating registration and licensing, b. Rebate on import of machinery / equipment.	Members: * DG (Population) * DG (Health) * Country Director
viii.	Concession / waivers on commercial taxes.	(GHSCP).

We will appreciate if USAID may engage an appropriate 2. organization / consultant to carry out the feasibility study.

With best regards,

Yours faithfully,

au (ABDUL GHAFFAR KHAN) Director General (P)

Ph.9216280

Ms. Monica Villanueva MCH Team Leader USAID Office Islamabad

Copy to:-

- 1.
- SPS to Secretary, M/o NHSR&C, Islamabad Dr. Muhammad Tariq, Country Director, Global Health Supply Chair Programme Procurement and Supply Management, Islamabad 2.

an N Director General (P)

ANNEXURE- II: USAID PAKISTAN CONCURRENCE TO THE PPW REQUEST



May 09, 2016

Mr. Abdul Ghattar Khan Director General, Population Program Wing Ministry of National Hearth Services, Regulations and Coordination LG&RD Complex, G-5/2, Islamabad

Subject: Request for Commissioning of Feasibility Study on the Manufacturing of Contraceptives in Pakistan

Dear Mr. Khan,

Thank you for your letter dated April 28, 2017 requesting USAID to engage an appropriate consultant to carry out the leasibility study on the manufacturing of contraceptives in Pakistan. USAID is happy to provide technical assistance for this request through the Producement & Supply Management (PSM) project. We have advised the PSM project to work closely with you and the Population Programme Wing (PPW) to carry out and complete the requested feasibility study as outlined in your letter.

We look forward to greater future collaboration.

Sincerely, Monica Villanueve

MCH Team Lead/USAID Pakistan

Copy for information:

- 1. Dr. Assad Hafeez, Director General, McNHSR&C, Islamabad
- 2. Sargita Patel, Director Health Office, USAID Pakistan, Islamabad
- 3. Dr. Muhammad Tariq, Country Director, USAID GHSC-PSM, Islamabad

ANNEXURE- III: PUBLIC SECTOR CONTRACEPTIVE DATA (2007 – 2010)

	Total Consumption of Contraceptives of Provincial / Regional Population Welfare Departments for the Period July-2007 to June 2010										
Year											
2007-08	55502062	2701914	150841	50706	57948	519733	1527729	511692	1400		
2008-09	66358006	3305675	144000	76703	728354	823811	1561595	758495	1545	886	
2009-10	41364808	3343099	68817	48887	662887	96508	1336905	905182	0	2171	
2010-11	71383308	3356055	120068	52678	782922	291453	946500	857025	1192	426	
TOTAL	234608184	12706743	483726	228974	2232111	1731505	5372729	3032394	4137	3483	

Total Consumption of Provincial Health Program (PHC Project) For The Period Of July-2007 To June 2010							
Year	Condom	COC	DMPA				
2007-08	163368000	4993200	0				
2008-09	168984000						
2009-10	10544976	3455500	75500				
2010-11	100649884	6503040	1030400				
Total	443546860	14951740	1105900				

Private Sector 5 Years consumption data as extracted from cLMIS

	Private Sector Yearly Report for Stakeholder(s) = 'All' And Indicator = 'Consumption' (2012-16)										
Year	Condom	POP	COC	ECP	Copper-T-380A	Safe Load	1-Month Inj	3-Month Inj	Implants	Multiload	2-Month Inj
2016	10,398,761	0	82,084	191,461	35,634	5,032	9,858	41,568	763	13,245	27,323
2015	11,177,743	0	93,321	181,418	37,300	1,743	10,261	42,966	1,269	20,413	31,943
2014	11,187,177	10,118	109,568	200,169	25,322	1,961	14,042	52,027	2,219	34,720	37,503
2013	16,096,454	3,094	183,355	238,990	14,932	3,070	19,904	67,443	699	66,891	65,918
2012	8,696,968	9,335	109,739	132,042	17,283	1,651	15,431	48,314	955	29,888	59,032